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Abstract
It is well documented that the administration of succinylcholine (SCh), also
known as suxamethonium, with general anesthesia causes muscle
fasciculations, which may cause severe postoperative myalgia. However, such
an association has not been well documented. Many authors have postulated
that such pain is secondary to damage produced in the muscle during
fasciculation. As a result, it is acceptable standard anesthetic practice to aim to
prevent fasciculations when administering SCh during the administration of
general anesthesia.
Today, studies utilizing subtherapuetic doses of nondepolarizing
neuromuscular blockade have shown the greatest promise in reducing
postoperative myalgia secondary to the use of SCh. This study has examined
and compared the efficacy of pretreatment with lidocaine, atracurium, and the
combination of the two in relation to the incidence and severity of postoperative
myalgia. As statistical significance was not expected with such a small pilot
population, this study was designed to determine the feasibility of conducting a
larger study. Additionally, trends within this population were further examined to
determine clinical significance.
. This study was a prospective, double-blinded randomized clinical study
utilizing 15 subjects who met inclusion criteria, and gave informed consent to
participate in the study. Each patient was randomly assigned to one of three
experimental groups that included lidocaine, atracurium, or a combination of the
two medications. Each group followed the same study protocol.
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Participants were followed every 24 hours for three days. Data collected was
based on a postoperative myalgia survey of 14 questions to ascertain myalgia
from routine postoperative discomfort. The answers were then graded on a
Likert scale (postoperative myalgia evaluation scale). In this way data collection
not only included those having myalgia, but also took into account the intensity of
postoperative myalgia. Data analysis compared the groups, looking for a
statistical significant difference to determine whether one pretreatment
medication was better than another in preventing postoperative myalgia.
As expected, statistical significance was not found among the three
pretreatment groups in relation to amount or intensity of postoperative_ myalgia.
In other words, one pretreatment group did not show improved efficacy over
another pretreatment group. However, several trends were identified, suggesting
that each pretreatment medication may have advantages and disadvantages that
may signify clinical significance, although not statistically significant.
In conclusion, this study proved to be feasible, and identified many new
factors such as physical health status, cigarette smoking, medication therapy
prior to surgical intervention, surgical type, and surgical position that may
contribute to the phenomena of postoperative myalgia. Therefore, further
research in this area is warranted.
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Chapter I
Introduction
Griffith & Johnson documented the first case of using human neuromuscular
blockade during general anesthesia in 1942. Unauthenticated Curare, by
Squibb, was administered to 25 patients experimentally. The investigators found
that it provided excellent muscle relaxation without detrimental effects to the
patient. However, their study concluded the following:_
Its scope of usefulness is limited because of its somewhat fleeting action, and
because it is in no sense an anesthetic agent. It is a potentially dangerous
poison, and should be used only by experienced anesthetists in well-equipped
operating rooms; but we have been so much impressed by the dramatic effect
produced in every one of our patients that we believe this investigation should
be continued (p. 420).

.- ·:

,J

'=

Today, intraoperative administration of neuromuscular blocking agents is
routinely utilized to facilitate endotracheal intubation associated with general
anesthesia, as well as provide skeletal muscle relaxation for optimal surgical
conditions (Stoelting & Miller, 2000). Multiple new pharmacological agents,
which provide akinesia, have been developed and refined over the last fifty
years. In each instance, the goals of scientists have been to develop agents that
provide the maximum desirable muscular paralysis while minimizing the
undesirable side effects of the agents. Additional uses of neuromuscular
blocking agents during this same time period have expanded to patient care
areas outside the operating room, enabling other providers to administer such
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agents. Situations where neuromuscular blocking agents may be used in the
care of patients outside of the surgical arena include assisting ventilation in
critically ill patients within the Intensive Care Unit, decreasing the muscle activity
during electroconvulsive therapy, and providing an emergent airway to a patient
within the Emergency Department (Pino & Basta, 1998). Such agents have
become a mainstay not only for the anesthesia providers' arsenal, but for other
medical professionals as well.
The Neuromuscular Junction
As described in Table 1, there are currently eleven distinct neuromuscular
blocking agents available within the United States. Skeletal muscle paralysis is
produced by the action of these agents and their ability to "block" or interrupt
nerve impulses at the neuromuscular junction. Based on the mechanism of
nerve interruption, onset, and duration (se� Table 1), each agent is classified as
either a depolarizing or a nondepolarizing agent (Stoelting, 1987). Pertinent to
understanding this author's work is the definition and description of how
neuromuscular blocking medications act at the cellular level. Therefore, for
clarity and unification, a brief review from this authors perspective will be
presented in the following section. A description of the normal neuromuscular
junction and the associated mechanisms of action for each class of
neuromuscular blocking agents will be reviewed.
The neuromuscular junction, also referred to as a myoneural junction, is the
area between a prejunctional motor nerve fiber and a postjunctional skeletal
muscle (Resnick & Henze, 2000). Transmission of a nerve impulse depends
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Table 1: Neuromuscular Blocking Agents
Agent

Classification

Onset

Duration

Action

Succinylcholine Depolarizing
30-60 sec
(SCh)
Mivacurium
Nondepolarizing 2-3 min

5-15 min

Ultrashort

20-30 min

Short

Atracurium

Nondepolarizing 2-3 min

30-60 min

Intermediate

cis-Atracurium

Nondepolarizing 2-3 min

30-60 min

Intermediate

Rocuronium

Nondepolarizing 1-1.5 min

30-60 min

Intermediate

Vecuronium

Nondepolarizing 3-4 min

30-60 min

Intermediate

Doxacurium

Nondepolarizing 12 min

60-90 min

Long

· Metacurium

Nondepolarizing 1-2 min

60-90 min

Long

Pancuronium

Nondepolarizing 2-3 min

60-90 min

Long

Pipecuronium

Nondepolarizing 3-4 min

60-90 min

Long

d-tubocurare
(OTC)

Nondepolarizing 3-4 min

60-90 min Long, but no
longer
available

Adapted from Morgan & Mikhail, 1996
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largely on the influx of calcium at this junction. Such an influx of calcium ions
causes a release of the neurotransmitter acetylcholine from the nerve terminal.
Once acetylcholine binds to the postjunctional receptors on the skeletal muscle,
changes in membrane potential create an action potential difference that leads to
skeletal muscle contraction (Stoelting & Miller, 2000). Relaxation of the skeletal
muscle is facilitated by the enzyme acetylcholinesterase. This enzyme
hydrolyzes acetylcholine, thus, eliminating from the neuromuscular junction the
principle neurotransmitter responsible for the propagation of action potentials in
skeletal muscle, which subsequently leads to muscular relaxation (Stoelting &
Miller, 2000).
Depolarizing Neuromuscular Blockade
Of the eleven neuromuscular blocking agents available within the United
States, only succinylcholine (SCh) is classified as a depolarizing agent.
Chemically, its structure can be described as two acetylcholine molecules bound
together. Therefore, SCh mimics the action of acetylcholine at the
neuromuscular junction by creating an action potential within the skeletal muscle
after the opening of prejunctional sodium channels, and causing a myoneural
depolarization (Stoelting & Miller, 2000). However, because hydrolysis of SCh
within the synaptic cleft is much slower than acetylcholine, each muscle cell
remains depolarized, and the numerous action potentials which occur result in
muscle twitches or fasciculations that can be observed. Relaxation of the
skeletal muscle occurs because SCh occupies the postjunctional receptor site,
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and sodium channels cannot reopen until the end plate repolarizes (Morgan &
Mikhail, 1996).
Because of its chemical structure and metabolism by plasma cholinesterase,
SCh has the two most desirable effects of any skeletal muscle relaxant available
today: (1) fast onset and (2) short duration. Such properties allow for quicker
control of the airway following loss of consciousness after the induction of a
general anesthetic, facilitation of endotracheal intubation, and faster recovery of
spontaneous respiration following muscular paralysis. Therefore, the use of SCh
allows for safer care to the unconscious anesthetized patient when rapid
securing of the airway is necessary.
Nondepolarizing Neuromuscular Blockade
Currently, there are ten nondepolarizing neuromuscular blocking agents
available for use in the United States. All of the their mechanisms of action are
similar and involve the competitive inhibition ·of acetylcholine at the postjunctional
receptor on the skeletal muscle at the level of the neuromuscular junction.
Excessive quantity of non_depolarizer molecules at this site effectively prevents
ion permeability, cellular depolarization, and ultimately inhibits the generation and
propagation of action potentials. This disruption of cellular electrical activity
allows for flaccidness of the skeletal muscle to predominate (Morgan & Mikhail,
1996).
Nondepolarizing neuromuscular blocking agents are classified into three
groups according to their duration of action. These groups include short acting
agents, intermediate acting agents, and long acting agents. However, in spite of
5

the suggestion made by the name, even the individual drugs in the short acting
group have a longer time until onset and longer duration than SCh (see Table 1).
SCh remains the best medication currently available for enabling an anesthesia
provider to rapidly secure the surgical patient's airway. The ability to safely,
efficiently, and rapidly control the respiratory functions and airway is one of the
most important actions of an anesthesia provider (Morgan & Mikhail, 1996).
Despite many desirable effects, SCh also displays many adverse actions,
which range from nuisance to serious. These side effects are listed in Figure 1.
Obviously, the severe reactions are more important (Stoelting� 1987). Many
studies exist on these reactions and conditions and much is known about these
complications and their treatments. There is, however, a paucity of information ·
regarding surgical patients and post-SCh administration myalgia. This paper will
concentrate on the iatrogenic causes and treatments for SCh-induced
postoperative myalgia, as it relates to the "gate control theory of pain".
Succinylcholine-induced Postoperative Myalgia
Past studies have indicated that the incidence of SCh-induced postoperative
myalgia ranges from 1.5% - 89%, with the most common incidence being 50%
(Wong & Chung, 2000). Certainly this is a sizable variation, and the lack of
consistent scientific data on this subject is another important factor that
encourages this author's current study. The most postulated mechanism for
myalgia following SCh administration is believed to be from what is termed
fasciculation (Wong & Chung, 2000). This phenomenon occurs almost

6

Adverse Side Effects of Succinylcholine
Cardiac dysrhythmias
Sinus bradycardia
Junctional rhythm
Sinus arrest
Fasciculations
Hyperkalemia
Myalgia
Myoglobinemia
Increased lntraocular pressure
Increased lntragastric pressure
Trismus
Allergic reactions
Trigger for Malignant Hyperthermia

Adapted from Stoelting & Miller, 2000

Figure 1: Adverse Side Effects of Succinylcholine
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immediately after the administration of SCh, and is observed as uncoordinated ,
uncontrollable, vigorous twitching of single muscle groups innervated by single
motor nerve fibers (Anderson, Anderson, & Glanze, 1 998 pp. 61 6). It occurs
over the entire body without synchronous activity, allowing for shearing forces
and biochemical damage to occur to the muscle cells and tissues. Such damage
is believed to be a major contributing factor leading to postoperative muscle
soreness (myalgia) (Wong & Chung, 2000).
Although it was originally postulated that postoperative muscle pain was
linked to the use of SCh and its depolarizing action that caused fasciculations,
the exact pathogenesis is still unknown. Many studies have concluded that the
mechanism for SCh-induced fasciculation is a prejunctional phenomenon.
Similarly, respected researchers have confirmed the correlation between
fasciculation and SCh administration (Kitamura S, Yoshiya I, Tashiro C, & Nefishi
T, 1 98 1 ). However, it does not appear that the same relationship occurs

.

.

between SCh-induced fasciculation and postoperative myalgia (Sosis, Broad,
Larijani & Marr, 1 987). Studies attempting to correlate muscle damage
secondary to fasciculation, with changes in serum creatine phosphokinase levels,
lactic acid levels, and electrolyte changes, have all discredited this theory. No
studies to date have confirmed a statistically significant relationship between
muscle damage secondary to the use of SCh, and postoperative myalgia (Wong
& Chung, 2000). Therefore, these findings suggest that such muscle pain must
occur from some additional mechanism, other than exclusively from muscular
fasciculation.
8

The results of some studies have yielded data that suggests postoperative
myalgia may not be associated at all with fasciculation, nor is it associated with
the use of SCh (Mingus, Herlich, & Eisenkraft, 1990). Recent studies have
demonstrated that no significant difference in postoperative myalgia is found
between those subjects who receive SCh and groups of subjects that receive a
nondepolarizing agent (Mingus, Herlich, & Eisenkraft, 1990). Few studies have
determined that myalgia may occur even in the circumstance when SCh
administration is avoided ·and only nondepolarizing agents are utilized (Trepanier,
Brousseau, & Lacerte, 1988).

Regardless of the cause, for those individuals

who experience pain, the occurrence of postoperative myalgia is viewed as
unacceptable. A closer look at the complex process of how pain is sensed,
transmitted, modulated, and perceived may contribute to a better understanding
of how to treat patients who experience this type of discomfort.
Myalgia
Postoperative myalgia is usually self-limiting in duration, ·and occurs up to
three days postoperatively, with 24 to 48 hours being the most prominent time
frame (Mikat-Stevens, Sukhani, Pappas, Fluder, Kleinman, & Stevens, 2000). It
is often compared to the feeling one obtains after aggressively working the
muscles, as may result from a period of strenuous physical exercise. It may
occur in the chest wall, the upper abdomen, shoulders, neck, and back
(Stoelting, 1987). Although the extent of muscle pain is generally mild, some
patients may experience debilitating effects requiring bed rest and analgesic
therapy for several days postoperatively. Even though the origin of such pain
9

remains unknown, explanations for the wide variance in occurrence and severity
can be explained by the gate control theory.
· This theory was first proposed in 1965, and continues to be the basis for
effective postoperative pain management (Melzack & Wall, 1965). Melzack and
Wall suggested that pain is transmitted from a peripheral site, such as the skin
(or a muscle), to a specialized group of cells within the dorsal horn of the spinal
cord known as the substantia gelatinosa. This area acts as a gate and responds
in one of two ways: opening to transmit signals (as in the noxious stimuli
associated with myalgia) to higher centers, or closing and thereby inhibiting the
transmission (as by the actions of analgesics).
Although such a theory may sound simple, there are a complex series of
physiologic responses that occur between the area of tissue damage
(fasciculation) and the perception of pain (postoperative myalgia). Such
complexity is referred to as nociception. Four physiologic processes trigger
nociception, or pain perception: transduction, transmission, modulation, and
perception (Ferrante, 1998).
Transduction, the first response to occur, happens upon administration of
SCh.

For those who believe fasciculation has a correlation to postoperative

myalgia, it is theorized that the muscle tissue becomes injured by the
fasciculation, and potassium is released into the extracelluar fluid as a result of
this injury or damage. Potassium is one of many pain-producing substances that
stimulate a specialized group of sensory receptors called nociceptors. Other
substances include hydrogen, seratonin, histamine, prostaglandins, and
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bradykinins. Collectively these are known as algesic agents and, upon
stimulation of the nociceptors, they cause electrochemical events at sensory
nerve endings (Sackett & Cannon, 2000).
At this point the second step of nociception, transmission, occurs. The gate is
opened as the propagation of electrical events is sent to the higher centers of the
peripheral nervous system (PNS) and central nervous system (CNS). Such
stimulation allows for the fourth process: perception of pain (Ferrante, 1998).
Substance P is released within the cerebral tissue upon stimulation. It is this
substance that conveys pain information in the cognitive centers of the brain and
thereby allows for this stimulation to be identified as pain perception and
associated responses enacted. Although transmission to the CNS occurs
primarily through small diameter A-delta and C-fibers, interconnections between
other sensory pathways can occur. One such pathway includes A-beta and A
alpha fibers. Stimulation of these large-diameter, fast, myelinated fibers causes
the gate to close and prevents or inhibits transmission to the higher neural
centers (Sackett & Cannon, 2000). Modulation, the third process, prevents the
release of Substance P and consequently the perception of pain (Sackett &
Cannon, 2000). It is this author's bel ief that it is this interplay between fibers.that
may most plausibly provide the explanation for the occurrence of such a wide
range (1.5% - 89%) and severity of reported postoperative myalgia.
Although studies up to this point in time have not determined the mechanism
by which postoperative myalgia occurs, it has been determined that the following
groups of individuals have a higher incidence of exhibiting such postoperative
11

muscle soreness: females greater than males, individuals between the ages of 8
and 50 (Mingus, Shamsi, Recant, Eisenkraft, 1 996) , those persons who are
ambulatory immediately after surgery (Oxorn, Whatley, Knox, & Hooper, 1 992) .
those patients undergoing minor procedures, and people who are less physically
fit than would be optimal (Newman & Loudon, 1 966). Additionally, without any
firm explanation, it has been observed that pregnancy appears to decrease
postoperative myalgia (Crawford, 1-9 71 ). Lastly, there does not appear to be an
association with different ethnic backgrounds (Houghton, Aun, Gin, Lau, & Oh,
1 993).
Many techniques have been attempted to prevent postoperative myalgia, and
it seems as though the science has come full circle in the last 50 years. The
current "gold standard" for prevention of postoperative myalgia in patients who
receive SCh is through use of pretreatment doses of nondepolarizing agents.
Despite critical opinions that such agents may cause difficulty with intubation,
weakness, diplopia, difficulty in breathing, and prolongation of neuromuscular
blockade, such agents consistently cause a 30% reduction of postoperative
myalgia (Pace, 1 990). Until further studies can demonstrate an alternative that
constantly and dependably reproduce the same or similar outcomes with regard
to the reduction of postoperative myalgia in patients who receive SCh,
nondepolarizing agents will continue to be the current standard of treatment.
Many studies have implicated the use of lidocaine for reliable prevention of
postoperative myalgia in association with SCh use. Of the current available
studies, all but one have suggested that lidocaine is of equal efficacy, and is
12

safer than the traditional treatment of nondepolarizing agents. Additionally,
multiple authors' studies agree that combination therapy with lidocaine and a
nondepolarizing neuromuscular blocking agent has shown to more significantly
improve outcomes of measured pain in subjects receiving SCh perioperatively.
Therefore, the focus of this study will be to compare the differential effects of
atracurium and/or lidocaine on SCh-induced postoperative myalgia as it relates
to the gate control theory of pain. The null hypothesis is as follows:
Null Hypothesis
There will be no difference in postoperative myalgia in subjects receiving SCh
who also receive one of three pretreatments: atracurium, lidocaine, or the
combination of atracurium and lidocaine.
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Chapter II
Review of the Literature
The Development of Succinylcholine
· 1n 1906, Hunt & Taveau were the first to synthesize SCh. They were looking
for agents that would maintain hemodynamics during general anesthesia in
anesthetized animals (Hunt & Taveau, 1906). Since they were using SCh in
conjunction with d-tubocurarine (DTC), the muscle relaxant properties of SCh
were not recognized. In fact, this association was not made until 1949 (Churchill
Davidson, 1984). Within a year of this discovery, SCh was being utilized in small
doses as a muscle relaxant during general anesthesia in humans (Foldes,
McNall, & Borrego-Hinojosa, 1952). Today, this drug continues to be widely
utilized by anesthesia professionals in the implementation of muscular paralysis
for subjects undergoing surgical intervention.
Side Effects of Succinylcholine
By the end of 1952 adverse side effects of SCh were first being noted.
Although not the focus of the original study on SCh, the initial side effect
identified was that of prolonged respiratory depression. This was attributed to
the administration of "unnecessarily high doses of succinylcholine" (Foldes,
McNall, & Borrego-Hinojosa, 1952, p. 600). However, further study resulted in an
association of SCh termination with plasma cholinesterase, the mechanism by
which SCh is metabolized, and the cause for occasional extended action of SCh
was identified. As a result of their research, prolonged respiratory depression in
subjects who were administered SCh was correlated to those subjects who had
15

low levels of plasma cholinesterase (Foldes, McNall, & Borrego-Hinojosa, 1952).
Others confirmed such findings the very same year (Evans, Gray, Lehmann, &
Silk, 1952).
Reports of a possible relationship between fasciculation and postoperative
myalgia started infiltrating the literature in 1952 (Brodsky & Ehrenwerth, 1980).
In one study comparing inpatient subjects to outpatient subjects, Churchill
Davidson found that SCh caused marked postoperative myalgia despite the fact
that the surgical procedure may have been minor (Churchill-Davidson, 1 954).
Interestingly enough, the author compared groups that were equal in terms of
group size and age, and found that outpatient subjects had a significantly higher
rate (66%) of muscle pain than was observed in the inpatient subjects population
(13.9%). This is a similar finding when compared to the majority of today's
studies (Wong & Chung, 2000).
Treatments for the Prevention of Postoperative Myalgia
The previously noted study by Churchill-Davidson was the first to attempt to
find a treatment for the prevention of postoperative myalgia. The first use of
gallamine, a nondepolarizing neuromuscular blocking agent, was used in
conjunction with SCh in an effort to abolish fasciculation and prevent
postoperative myalgia. Churchill-Davidson found that pretreatment with small
doses of gallamine, prior to the administration of SCh, totally abolished
fasciculation within both groups. Additionally, although not completely resolved,
the incidence of postoperative myalgia for outpatient subjects decreased from
66% to 40%. Complete abolishment of both fasciculation and postoperative
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myalgia for the inpatient subject group was achieved. These initial findings
appeared to offer support that fasciculation and postoperative myalgia were
directly related (Churchill-Davidson, 1954).
Further studies by Foster, in 1960, determined the incidence of myalgia to be
increased among ambulatory outpatient subjects. Additionally, he identified
many facts about myalgia in relation to SCh administration, which still hold true
today. These included the following: Postoperative myalgia occurs less
frequently in subjects over the age of 60, there is a low incidence of pain in
children, and muscle pains varied in accordance to the type of surgery (Foster,
1960). Furthermore, he confirmed that gallamine lowered the incidence and
severity of postoperative myalgia. Despite this encouraging finding, he
concluded that the use of nondepolarizing agents, as a pretreatment prior to
SCh, should not be recommended. Such agents were found to cause marked
respiratory depression or airway difficulties at the termination of the procedure
(Foster, 1960). Others, throughout the literature of that time, agreed with
Foster's supposition. In 1977, Baraka declared the competitive and antagonistic
affects of SCh were thought to delay the onset and decrease the degree of
neuromuscular blockade. Therefore, for purposes of preventing SCh-induced
postoperative myalgia, choosing a nondepolarizing agent for intubation and
completely avoiding the administration of SCh would be a better choice within the
context of the anesthetic plan (Baraka, 1977).
Because of such effects associated with the use of nondepolarizing agents as
a pretreatment for the prevention of postoperative myalgia in subjects who have
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received SCh , other methods have been investig ated in the last 50 years that
have followed Churchill-Davidson's seminal work in th is area. Within the
literature, there are at least 1 3 other treatments that have been stud ied in an
attempt to prevent or lessen postoperative myalgia. These include self-taming ,
stretching exercises , magnesium sulfate , propofol , vitamin C, dantrolene,
lidocaine, calcium gluconate, benzodiazepines, chlorpromazine,
aspirin/nonsteroidal anti-inflammatory d rugs, phenytoin, altering ind uction agents,
and dosage/timing of SCh administration (Wong & Chung, 2000). Some have
shown to be successful, while others have failed . The following section will
further describe the rational for, and success or failure of, each of these
treatments as they appear in the cu rrent literature.
Self-taming
I n much the same way a small dose of a nondepolarizing agent is given as a
pretreatment for the prevention of myalg ia associated with SCh administration ,
giving small doses of SCh prior to the fu ll dose has been attempted for the same
reason . This idea is known as "self-taming" (Baraka, 1 977). It is thought that
the taming effect desensitizes the neuromuscular junction . Therefore , excitation
between the nerve terminals and the muscular membrane cannot occur allowing
for decreased fasciculation . Additionally, unlike the affects ·caused by
pretreatment with a nondepolarizing agent, onset and duration of the block can
be preserved (Baraka, 1 977).
In 1 979, Brodsky and Brock-Utne found a 25% incidence of fasciculation
when using a self-taming tech nique as described by Baraka . This is very similar
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to Baraka's results of a 20% incidence. However, unlike Baraka, Brodsky and
Brock-Utne found no relationship between this decrease in fasciculation and
postoperative myalgia. Therefore, they concluded there was no advantage to
utilizing a "self-taming" technique for the purpose of preventing postoperative
muscular soreness in conjunction with SCh administration.
Like Churchill-Davidson and Foster's studies, Brodsky and Brock-Utne (1979)
found an increased incidence of postoperative myalgia in subjects who ambulate
(outpatient subjects). However, they emphasized the following:- "muscle aches
may occur postoperatively even when succinylcholine has not been used, and it
is impossible to differentiate SCh-induced myalgia from muscle soreness due to
other causes" (p. 267). This provides fu rther supportive evidence for what we
believe today, which is that fasciculation and postoperative myalgia may not be
directly associated. Therefore, prohibiting fasciculation may not be the
mechanism by which to improve patient outcomes in relationship to postoperative
muscular pain.
Although true, the above statement by Brodsky and Brock-Utne takes into
account only part of the phenomenon. There are numerous studies throughout
the literature comparing the incidence of postoperative myalgia with the use of
depolarizing agents and nondepolarizing agents, and these studies fail to support
Brodsky and Brock-Utne's statement. Trepanier, Brousseau, and Lacerte (1988)
compared SCh with atracurium in relation to postoperative muscle pain. The
incidence of postoperative myalgia among the group that received SCh was
76%, and the group who received atracurium was 23%. Therefore, these
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authors concluded the use of atracurium significantly reduced postoperative
myalgia in comparison to SCh.
However, when pretreatment doses of a nondepolarizing agent are utilized
prior to the administration of SCh, and these subjects are compared to the
members of a group who receives only a nondepolarizing agent, there is
evidence to support Brodsky and Brock-Utne's statement. Deehan, Henderson,
and Stewart (2000) compared subjects who received SCh after being pretreated
with gallamine to subjects who received only mivacurium. Although their findings
found a 26% incidence of postoperative myalgia in the pretreated SCh group,
and only a 9.5% finding in the mivacurium group, they were not statistically
significantly different. These findings provide additional evidence that
postoperative myalgia may result from causes other than SCh exclusively.
The study findings of Mikat-Stevens, Sukhani, Pappas, Fluder, Klienman and
Stevens (2000) corresponded to the findings of the research study conducted by
Deehan and associates. These investigators compared a group of subjects who
received SCh following pretreatment with OTC to a group of subjects who only
received mivacurium. Again, they found that the pretreated SCh group had an
increased incidence of myalgia at 2 1 %. These findings, however, were not
significantly different from the 1 8% incidence noted in the mivacurium group.
Thus, like Deehan and associates, these authors concluded that pretreating
subjects with nondepolarizing neuromuscular blocking agents, prior the
administration of SCh, does not cause a decrease in postoperative myalgia.
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Stretching Exercises
It is known that athletes who stretch prior to exercise have decreased muscle
damage and pain afterwards (Harris, 1984). MaGee & Robinson ( 1987)
theorized that perhaps the same would be true for subjects undergoing
anesthesia requiring the use of SCh for endotracheal intubation. They postulated
that the stretch receptors on the muscle fibers could undergo desensitization in
much the same way self-taming occurs. Their study concluded with a significant
finding of only 15% of the experimental stretching group having postoperative
myalgia, while 55% of the control group reported pain. Thus, signifying that
stretching prior to the administration of SCh decreased postoperative myalgia.
Although not the focus of this study, it is interesting to note that MaGee &
Robinson ( 1987) also found a correlation between fasciculation and the degree
of pain: The greater the measured fasciculation, the greater degree of reported
postoperative pain. Interestingly, in many of today's studies, this correlation does
not appear to occur.

Magnesium Sulfate
A classic example where absence of fasciculation does not coincide with an
absence of postoperative pain involves the administration of magnesium.
Specifically, pretreatment of magnesium sulfate does not diminish complaint of
postoperative discomfort following the administration of SCh. Theoretically,
magnesium sulfate has neuromuscular blocking properties and should abolish
fasciculation. If the absence of fasciculation equates to the absence of
discomfort, subjects adequately treated with magnesium sulfate should not
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fasciculate, and so should have their pain prevented. A study performed by
Chestnutt and Dundee (1985) found that magnesium significantly decreased
fasciculation, nearly abolishing it. However, only slight decreases were identified
in relation to postoperative myalgia in their study subjects. 64% of the treated
group had postoperative pain, as opposed to 80% of the untreated group, not a
significant difference in regards to their study.
Stacey, Barclay, Asai, & Vaughan (1995) confirmed Chestnutt and Dundee's
finding. They discovered a significant decrease in fasciculation with the use of
magnesium sulfate, but no difference in postoperative myalgia. Oddly, in similar
fashion to the findings of Chestnutt and Dundee, serum potassium levels were
found to be normal. Therefore, despite the abolishment of fasciculation and
normal potassium levels, subjects pretreated with magnesium sulfate continue to
have postoperative muscle soreness. Therefore, it was concluded that
magnesium sulfate shows no promise in being a pretreatment for the prevention
of postoperative myalgia in subjects who receive SCh.
Propofol

In terms of fasciculation, two recent studies have shown agreement with the
above noted findings. First, Mingus, Shamsi, Recant, and Eisenkraft's (1996)
study consisted of the following three groups: those who received thiamylal/SCh
in group one, propofol/ SCh in group two, and propofol/saline in group three. All
groups were demographically comparable, and none demonstrated significance
in incidence or severity of postoperative myalgia despite significant differences in
measured fasciculation between groups' one, two, and three. Although group
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three did not receive SCh, 30% of the subjects in this group reported
postoperative pain. In contrast, 50% of the subjects within group two, who
received SCh, complained of postoperative myalgia. These results were not
considered significant, therefore, allowing Mingus and associates to conclude
that postoperative myalgia was not associated with fasciculation.
Manataki, Arnaoutoglou, Tefa, Glatzounis, and Papadopoulos (1999),
performed a study comparing two groups of subjects. Both groups received
propofol and SCh for induction, but differed in their maintenance of anesthesia.
Group one was maintained with isoflurane, while group two received continuous
propofol. No significant correlation was found between fasciculation,
postoperative myalgia, or elevations in CPK between the group who had been
maintained using propofol, as compared to the group who was maintained with
isoflurane. Therefore, the authors concluded that fasciculation does not have a
correlation with muscle damage. Additionally, they contended that postoperative
myalgia and muscle damage are not caused by the same mechanism.
Vitamin C

Vitamin C is known to decrease muscle pain and soreness after
unaccustomed exercise. It provides protection to the endothelial lining of
capillaries, therefore preventing damage to muscle fibers (Syed, 1 966). Gupte
and Savant (1971 ) showed a decreased significance in the incidence of
postoperative myalgia with the administration of vitamin C perioperatively.
Currently, however, there are no studies that compare this intervention with other
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treatments (Wong & Chung, 2000). Therefore, this remains an area for future
study that may provide an alternative treatment for postoperative myalgia.

Dantrolene
Collier (1978) theorized that the more calcium released from the sarcoplasmic
reticulum within the muscle during depolarization, the greater the speed and
strength of resulting fasciculations. Ultimately, stronger fasciculations lead to
greater muscle damage and results in increased postoperative myalgia.
Confirmation of this became reality in Collier's first study. In this investigation, he
found an inverse relationship between calcium and potassium in those subjects
who developed pain and concluded that postoperative myalgia was a result of
muscle fiber damage, secondary ·to fasciculation, that was caused by the
enhanced release of calcium.
Since dantrolene interferes with intercellular calcium transfer, Collier ( 1 979)
felt it was an appropriate medication to decrease fasciculation and postoperative
myalgia. In his second study, 98 subjects were given dantrolene orally two hours
prior to surgery. Not only did he find a significant difference in the strength of
muscle fasciculation and potassium levels, he also found that myalgia decreased
from 56% to 4% between the pretreated group and those who were not
pretreated. Additionally, unlike the use of nondepolarizing agents as a
pretreatment, he did not identify any alteration in the action of SCh in conjunction
with dantrolene administration. Therefore, he concluded dantrolene to be an
efficient treatment for the prevention of postoperative myalgia in subjects who
received SCh.
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Another study with dantrolene performed by Gysai, Delisle, and Bevan (1 982)
failed to show a reduction in postoperative myalgia. However, this study utilized
small doses of intravenous dantrolene instead of the oral form. This was not the
first instance identified in the literature where an intravenous form of a medication
under investigation failed to have the same outcome, in reference to
postoperative myalgia, as the oral form. The authors recommended further study
of this subject matter in order to assess whether there was an association
between route of administration and postoperative discomfort following
intravenous SCh administration.
Fol lowing Collier's lead, and postulating that postoperative myalgia is a result
of muscle damage, Laurence ( 1 985) performed a study attempting to show a
correlation between dantrolene pretreatment and muscle damage. Rises in
myoglobin were measured to predict the amount of muscle damage. He
hypothesized that pretreated subjects would show decreased myoglobin levels,
thereby, indicating significantly less muscle damage had occurred. As
postulated, significant differences in the amount of myoglobin were found among
pretreated subjects verses those subjects who were not pretreated. Following
analysis of the data collected in his study, this author concluded that his results
agreed with Collier. His final conclusion was that oral dantrolene could
potentially be beneficial in the prevention of postoperative myalgia.
. Lidocaine
JE Usubiaga, Wikinski, JA Usubiaga, and Molina (1967) were the first to show
that pretreatment with intravenous lidocaine prevented postoperative myalgia, as
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well as a decrease in muscle soreness. They found minimal side effects
associated with lidocaine when it was given at doses of 1.5 mg/kg. In 1973,
Haldia, Chatterji, and Kackar replicated such findings by using 3-4 mg/kg of
lidocaine, showing decreased postoperative myalgia. Today, 1.5 mg/kg is the
most often used dose, as these past studies have shown equal efficacy between
this dose and higher doses. Additionally, such a dose is well below the toxicity
level of lidocaine.
In much the same way Collier found an inverse relationship among potassium
and calcium in relation to the use of dantrolene, Chatterji, Thind, and Daga
(1983) found a similar relationship with the use of lidocaine. Unlike their
predecessors, who believed that lidocaine prevented soreness by producing a
sedative effect, these authors concluded that lidocaine stabilized the cell
membrane and consequently restricted ionic movement. The effect of lidocaine
in subjects who received SCh was the suppression of muscle damage and the
prevention of postoperative myalgia.
Calcium Gluconate

Shrivastava, Chatterji, Suman, and Daga (1983) further investigated the
relationship between SCh administration and cellular damage. Specifically, they
examined the previously observed inverse relationship of increased serum
potassium and decreased serum calcium in relation to SCh-induced
postoperative myalgia. These individuals theorized that the administration of
calcium gluconate prior to the administration of SCh would prevent postoperative
myalgia. Although they could not identify the mechanism by which this occurred,
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they nonetheless observed that calcium gluconate significantly reduced the
incidence of muscle pains from 45% to 5%. Additionally, the severity of pain was
likewise reduced. A principle conclusion of these authors was that since similar
studies were limited, further research on calcium gluconate and its association
with postoperative myalgia was indicated before the use of this intervention could
be established as a beneficial treatment.
Benzodiazepines
As well as myoglobin changes, studies have found that the administration of
SCh can also cause electrolyte and other biochemical changes at the cellular
level. As the above studies have eluded, these alterations are hypothesized to
be a result of depolarization and muscle damage from fasciculation. In
agreement with the gate control theory, some studies have attributed increases
in serum potassium and creatine phosphokinase (CPK) as causative factors for
postoperative myalgia (Fahmy, Malek, & Lappas, 1979). Fahmy and associates
found that pretreatment with diazepam prior to SCh administration prevented
fasciculations, hyperkalemia, and subs�quent rises in CPK. Thus, they
concluded this intervention led to a significant decrease in postoperative myalgia.
In their work, only 12.5% of subjects receiving benzodiazepines experienced
postoperative myalgia as compared to 65% of subjects in the untreated group.
Eisenberg, Balsley, and Katz (1979) had similar results of decreased muscle
pain in subjects who received SCh as a component of their anesthetic plan, but
who were pretreated with diazepam. In their study, only 13% of the treatment
group displayed postoperative discomfort. This is contrasted to 33% of the
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control group's subjects. Although, serum potassium levels remained normal in
their study subjects, unlike Fahmy and associates, they found that CPK was
elevated within the pretreatment group. Reasoning for this finding remains a
mystery, and unlike the previous study, decreases in postoperative myalgia
occurred despite a rise in CPK.
Prior to these two studies, Verma, Chatterji, and Mathur (1978) had also
concluded that pretreating with diazepam decreased the incidence, · severity, and
duration of SCh-induced myalgia. Their results were similar to both of the above
studies. They found in subjects receiving intraoperative SCh, only 16% of the
subjects detailed postoperative myalgia with muscular pain after pretreatment, as
opposed to 60% experiencing pain without pretreatment. Although serum
potassium and CPK levels were not measured in this study, the outcome
remained the same. These authors suggested that pretreatment with diazepam
should be considered for decreasing postoperative myalgia in subjects receiving
SCh.
Chestnut, Lowry, Dundee, Panditt, and Mirakhur (1985), however, failed to
confirm the above detailed findings. In a comparison trial of diazepam,
midazolam, and DTC, these authors concluded that -postoperative myalgia was
not prevented by any of the benzodiazepine pretreatments. Interestingly enough,
the DTC group had less reported myalgia than the other groups. Additionally,
unlike the previous three studies, electrolyte and biochemical changes in these
authors' study subjects were found to be inconsistent among all groups.
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The unpredictable and inconsistent findings of the above detailed studies
cause this author to conclude that biochemical and electrolyte changes after the
administration of SCh may not have an association with postoperative myalgia.
Additional support for this notion is provided by the study of Mcloughlin, Elliot,
McCarthy, & Mirakhur (1992). Although their pretreatment was not diazepam, but
rather a variety of other medications, they reported that there was no correlation
between myalgia and rises of CPK. Therefore, they concluded that biochemical
changes and postoperative myalgia were separate and distinct entities.

Ch/orpromazine
Mcloughlin, Elliot, McCarthy, and Mirakhur (1992) provided some evidence
that chlorpromazine was effective in preventing postoperative myalgia. It is
thought that chlorpromazine inhibits phospholipase A2, a major enzyme, which is
ultimately responsible for the release of fatty acids. It has been postulated that
such release causes muscle damage, in turn causing postoperative myalgia.
Therefore, inhibition of this enzyme should prevent such damage and its
resultant myalgia. This concept was confirmed by their study. They found rises
in CPK, serum potassium, and serum calcium insignificant when chlorpromazine
was used as a pretreatment, indicating the preservation of muscle function.
Additionally, only 15% of the chlorpromazine treated subjects reported having
postoperative pain. Although Mcloughlin and associates reported that the use of
chlorpromazine should be further studied, Wong and Chung (2000) discourage
its use, noting the side-effect profile of chlorpromazine would outweigh the
benefits for its use in the prevention of postoperative myalgia.
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Aspirin/Nonsteroidal Anti-Inflammatory Drugs
As some of the above studies indicated, fasciculation results in muscular
damage and the release of CPK, myoglobin, and electrolyte disturbances. Work
performed by Kahraman, Ercan, Aypar, and Erdem (1993) found elevations of
enkephalins, prostaglandins, leukotrienes, and histamines in subjects that
fasciculated. Such chemicals are major causes of nociception and start the
cascade of events that fit into the framework of the gate control theory of pain
(Sackett & Cannon, 1999). Prostaglandins not only sensitize pain receptors, but
also potentiate the actions of histamine and bradykinins. Thus, the substances
allow for increased pain modulation and perception by the patient.
Kahraman and associates hypothesized that by inhibiting prostaglandins
perhaps postoperative myalgia could be decreased. Their study involved 34
healthy subjects undergoing elective ophthalmic surgery. Preoperatively each
subject within the treatment group received oral diclofenac, a nonsteroidal anti
inflammatory (NSAID), prior to the administration of SCh. They reported a 30%
reduction of postoperative myalgia in this experimental group, as compared to
the untreated group. Although these authors found no correlation be�een
myalgia and the severity of fasciculation, they concluded preoperative
administration of diclofenac nonetheless reduced postoperative myalgia.
Previous work performed by Mcloughlin, Nesbitt, and Howe (1988) found
similar results with the preoperative administration of oral aspirin. They identified
a 36% reduction in postoperative myalgia among those subjects who were
treated preoperatively with aspirin. These results, like those of other
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investigators discussed in the following section, were once again attributed to the
inhibition of prostaglandin synthesis. As previously noted, interrupting the
cascading events of the gate control theory, resulting in decreased pain
modulation and ultimately diminished pain perception. .
More recent studies using ketrolac (a NSAID), by Leeson-Payne, Nicoll, and
Hobbs ( 1994), did not support the findings of the previous two studies. They
enrolled 60 healthy subjects within their study and administered intravenous
ketrolac preoperatively. As mentioned, they concluded that ketrolac did not
significantly prevent postoperative myalgia in subjects receiving SCh
perioperatively. Their results were unexpected findings, since ketrolac is 350
times more potent in the inhibition of prostaglandins than aspirin. It is of
importance to note that just as intravenous dantrolene did not have the same
result as the oral form, here too a similar observation has been made with the
use of NSAIDS. Again, this topic has been identified as an area for needed
future study. Specifically, the question needing investigation is whether the oral
form of ketrolac would show a difference from the intravenous form, with respect
to postoperative myalgia in subjects receiving SCh in the perioperative period.

Phenytoin
Hartmen, Fiamengo, and Riker ( 1986) demonstrated that phenytoin
prevents fasciculation by a prejunctional mechanism. However, this study was
performed in vitro, and despite such findings, these results have not been
replicated in humans. In fact, Hatta, Saxena, and Kaul ( 1992) not only found that
there was no relation in the incidence of fasciculation, but there also was no
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relationship/correlation among fasciculation, serum potassium levels, and
postoperative myalgia when phenytoin was used as a pretreatment. Although
phenytoin did not significantly prevent fasciculation or changes in serum
potassium, they concluded that it significantly reduced postoperative myalgia by
as much as 18.3%. They postulated that such a finding was caused by the
stabilization of motor nerve terminals. As with calcium gluconate, there are
relatively few studies using phenytoin as a pretreatment for postoperative
myalgia. Therefore, much more research is indicated before we make changes in
our current methods or practices with regards to phenytoin usage for the
reduction of SCh related postoperative myalgia.
Nondepolarizing Agents
Since Churchill-Davidson's finding in 1954, that pretreatment of subjects with
gallamine significantly reduced postoperative myalgia, numerous studies have
been performed to assess the effectiveness of varying nondepolarizing agents on
this phenomenon. Although the exact mechanism is not fully understood, the
use of nondepolarizing neuromuscular blocking agents is currently the most
widely accepted practice for treatment and prevention of postoperative myalgia in
individuals who are to have SCh as part of their anesthetic plan (Deehan,
Henderson, & Stewart, 2000). For purposes of this author's review, 10 studies
will be examined in order to provide increased insight to this enigmatic
pretreatment for the prevention of postoperative myalgia in conjunction with SCh
usage.
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Because they were the first nondepolarizing agents available, gallamine and
DTC are the two most studied medications within the literature, which have been
used for the pretreatment of fascicul�tion and prevention of postoperative
myalgia. However, DTC is no longer commercially available due to agricultural
and manufacturing constraints. Although the literature is suggestive that DTC
prevented fasciculation better than any current modern nondepolarizing agents,
this drug will no� be a focus of this study since it is no longer commercially
available (Pinchak, Smith, Shepard, & Patterson, 1994). Sadly, it is anticipated
that this drug will never commercially resurface in the world of anesthesia again.
After Churchill-Davidson's original work, no less than_ six additional
researchers performed studies utilizing gallamine in the pretreatment of
postoperative myalgia in conjunction with SCh administration. Glauber (1966)
found that pretreatment significantly reduced postoperative myalgia in female
subjects, from 47.2% without pretreatment, to 16% with pretreatment. The same
phenomena did not occur among the male subjects in his study. Male subjects
reported a 48.4% incidence of experiencing pain without pretreatment, and
36.4% with pretreatment. Glauber made an interesting find through his work,
however, that remains important for modern day research in this subject area.
The pretreatment of DTC in his study was given as a single dose of 5 mg. It was
not based on body weight. Therefore, it could be concluded that pretreatment in
males did not reveal any statistical significance because the dose was not large
enough to counteract the effects of SCh in the heavier and more fully muscled
male subjects. This author believes that pretreatments should be based on
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mg/kg basis for any degree of scientific significance to be ascertained from study
results.
Brodsky, Brock-Utne, and Samuels (1 979) were the first to investigate the use
of pancuronium as a pretreatment for SCh-induced postoperative myalgia. They
used two groups that were identical with respect to age, weight, anesthetic
technique, and length of operation. Group one was pretreated with pancuronium,
while group two did not have any pretreatment. Ninety-five percent of subjects
within group two had fasciculation, while only 20% of group one exhibited
movement. Statistically, pancuronium made a difference in fasciculation.
However, in terms of postoperative myalgia, neither group had impressive
findings. Although those pretreated with pancuronium did have less myalgia
(20%), the measured difference was not significantly different from those who did
not receive pretreatment (35%) . Therefore, Brodsky and associates (1 979)
concluded that there was no correlation between fasciculation and postoperative
myalgia. Additionally, they stated that pancuronium "does not decrease the
incidence or severity of postoperative myalgia . .. " (p. 261 ).
O'Sullivan, Williams, and Calvey ( 1 988) performed a comparison study of
pretreatment doses of gal lamine, pancuronium, and taming doses of SCh. Their
findings were in agreement with many previous studies, in that gal lamine
inhibited fasciculation better than pancuronium. Additionally, they concluded that
there was not an association between fasciculation and postoperative myalgia.
However, in regards to postoperative myalgia, they found just the opposite from
the previous study. Pancuronium had a greater effect on postoperative myalgia,
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and significantly reduced postoperative pain better than gallamine. Ultimately,
they reasoned that gallamine acts at the prejunctional site to decrease the rate of
firing, and therefore decreases fasciculation. Pancuronium, on the other hand,
was postulated to work at the postsynaptic site and decreases postoperative
myalgia. Therefore, providing reasoning for what others have hypothesized
throughout the literature, that fasciculation and postoperative myalgia are caused
by different mechanisms.
Although varying results have been do_cumented throughout the literature,
atracurium is currently one of the most studied and most effective
nondepolarizing agents for the prevention of postoperative myalgia (Pace, 1 990).
Perhaps this is because it is metabolized by Hoffman elimination in addition to
being eliminated through ester hydrolysis, and therefore can be safely used for
even the sickest of subjects who may have hepatic and renal dysfunction. This
safety index is one reason why atracurium was chosen as the focus of this study.
The following section reviews several studies found within the body of literature
comparing atracurium to other nondepolarizing agents and their effectiveness in
reducing postoperative myalgia.
Sosis, Broad, Larijani, and Marr (1 987) compared atracurium, normal saline,
and DTC and measured for both fasciculation and postoperative myalgia in
subjects receiving SCh. They found that OTC prevented fasciculations better
than atracurium, but the reverse was true for postoperative myalgia. Although
the only significant finding was that both OTC and atracurium significantly
decreased postoperative myalgia when compared to saline, neither was
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significantly superior to the other. However, numerically, there is a 26%
difference between the two groups. Eighty-five percent of subjects pretreated
with atracurium were free from postoperative pain, while only 59% of subjects
treated with OTC reported the absence of postoperative myalgias.
Hochhalter (1996) found just the opposite of Sosis and associates. This
studies results indicated that atracurium, when compared to normal saline,
decreased fasciculation, but had little effect on postoperative myalgia in subjects
who received SCh. Additionally, Hochhalter concluded that there was no relation
between fasciculation and postoperative myalgia, as several subjects were
recorded as having very defining fasciculations, but no muscle soreness.
Although atracurium was effective in preventing fasciculation (73%), the
incidence of postoperative myalgia was not prevented, with 1 2% of the
pretreatment group having pain. Although this does not sound like much of a
difference when compared to other studies, this is a large dissimilarity
considering there was only a rate of 33% overall reporting pain during the first 24
hours.
Martin, Carrier, Pirlet, Claprood, and Tetraults' (1 998) study compared the
following agents: normal saline (control), OTC, vecuronium, atracurium,
rocuronium, and mivacurium. They observed the usual finding of 50%
postoperative myalgia within the normal saline group. However, myalgia was not
significantly diminished by any of the pretreatments. In terms of postoperative
myalgia, they concluded that there was not any advantage to pretreatment. In
fact, they noted that pretreatment could even be potentially dangerous, in that the

36

mivacurium group not only resulted in the need for a larger dose of SCh, but also
resulted in a prolonged paralytic block.
Tsui, Reid, Gupta, Kearney, Mayson and Finucane (1 998) compared
atracurium, rocuronium and normal saline. Unlike previous studies, they found
evidence that rocuronium significantly reduced both fasciculation and
postoperative myalgia in subjects who received SCh as a component of their
general anesthetic.

Although atracurium was found to reduce postoperative

myalgia, it was not until postoperative day number two that this finding became
significant. Therefore, it was concluded that rocuronium was a better choice for
the pretreatment of both fasciculation and postoperative myalgia than atracurium.
Previous work performed by Demers-Pelltier, Drolet, Girard, and Donati
(1 997) found similar results to Tsiu and associates. Their work compared
rocuronium, OTC, and normal saline in subjects who also received SCh. They
concluded that rocuronium and OTC were equivalent in preventing fasciculations.
However, like Tsui and associates, they found that rocuronium significantly
decreased postoperative myalgia over OTC . . Like many previous studies, this
investigation demonstrated that pretreatment with a nondepolarizing agent
delayed the onset of SCh and shortened the duration of the block. In this case,
rocuronium had much more of an enhanced affect than did OTC. In order to
prevent such a problem, higher doses of SCh would be needed. As previously
mentioned, this discovery opened inquiry to an additional confounding variable,
one that had not been anticipated prior to its identification. Did the increased
dose of SCh affect the degree or amount of postoperative myalgia?
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Because of varying results among studies comparing differing agents, it has
been suggested and demonstrated that combination therapy appears to be the
most useful method in preventing postoperative myalgia (Wong & Chung, 2000).
Until the exact mechanism of myalgia is determined, attacking investigation of
this subject at differing angles may be the best approach. Melnick, Chalasani,
Uy, Phitayakorn, Mallett, and Rudy ( 1987) found that OTC in combination with
lidocaine provided subjects who received SCh with less postoperative myalgia
than either medication used separately. The incidence of pain in the combination
group was only 8.3%. This was 30% less than the incidence reported in any of
the other groups. Their results, therefore, lead many authorities in this area of
investigation to the conclusion that combination therapy improves patient
outcomes in terms of postoperative SCh-induced myalgia.
Raman and San ( 1997) also found combination therapy to be effective in
reducing myalgias. Their study established that subjects pretreated with both
atracurium and lidocaine had a significantly lower incidence of postoperative
myalgia following SCh administration than those pretreated with each medication
separately. The control group had a 75% incidence, atracurium had a 35%
incidence, lidocaine had a 30% incidence, and the combination group only had a
5% incidence of postoperative myalgia. These findjngs support utilizing two lines
of attack, as lidocaine works as a cell membrane stabilizer. Although different
studies have demonstrated differing results, atracurium is thought by most to be
active at prejunctional sites (Wong & Chung, 2000).
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Although many facts about SCh have been known since 1 960, only 1 0 years
after the first routine use during general anesthesia, the definitive cause of
postoperative myalgia remains unidentified . Foster quoted the following passage
from a 1 960 journal article (p. 25):
Every time suxamethonium [succinylcholine] is used consideration must
be given to the indications for its use and the incidence of muscle pains
afterwards, and we must all hope that the chemists will produce a new
relaxant with the advantages of suxamethonium [succinylcholine] but
without its capacity for producing these pains.
How ironic, that nearly half a century later, we continue searching for the same
answers to questions that first were documented in 1 960.
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Chapter Ill
Materials and Methods
The overall purpose of this pilot study was to discover the feasibility and
practicality of subsequently implementing a full-scale study aimed at identifying
the best medication or combinations of medications that reduce postoperative
myalgia following the administration of SCh when it is utilized as part of a general
anesthetic. This pilot study examined and compared the efficacy of pretreatment
with atracurium, lidocaine, or the combination of these two medications in relation
to the reported incidence of postoperative myalgia in subjects who received SCh.
The Postoperative Myalgia Survey (PMS) was utilized to collect data regarding
muscle pain in subjects who had received SCh as a component of general
anesthesia at 24, 48, and 72 hours postoperatively. This instrument is a 14question survey that not only allows subjects to describe their pain both
quantitatively and qualitatively, but also allowed the researcher to distinguish
whether the pain being experienced by the subject was truly myalgia, rather than
some other type of related surgical discomfort. The researcher applied data
gathered from the utilization of the PMS to a second instrument, known as the
Postoperative Myalgia Evaluation Scale (PMES).
The PMES is a modification of the Visual Analog Pain Scale (VAPS) and was
used to rate and record the overall severity of the myalgia on a O - 3 Ukert scale,
based on the occurrence and severity of myalgia as it was described by the
subject. Because the focus of this study did not consider it adequate to only
report myalgia experienced by t_he subject, which was collected by the PMS, the
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PMES was employed to specify the incidence and severity of the reported
myalgia as it related to each of the three study groups.
Throughout the remainder of this chapter, this author will explore and present
operational definitions, the research design·, subject sample and setting, inclusion
and exclusion criteria, informed consent, study protocol, instrumentation, data
analysis, assumptions, study limitations, specific risks and protection measures,
and potential benefits as they relate to the pilot study.
Operational Definitions
As it is essential for all readers of this manuscript to assure consistent
understanding of some pivotal terminology, the following section lists the
operational definitions that should be used throughout the remainder of this
paper.
1. American Society of Anesthesiologists (ASA} - The American Society of
Anesthesiologists is an educational, research and scientific association of
physician anesthesiologists who have organized to raise and maintain the
standards of the medical practice of anesthesiology and improve the care
of the patient.
2. ASA Physical Status Classification (PSC) I and/or ASA PSC I I Describes the physical status of a patient at the time· of surgery.
Appendix A holds specific definitions.
3. Endotracheal Anesthesia - General anesthesia that is delivered to the
lungs through the trachea via an endotracheal tube.
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4. Endotracheal tube - A large tube that is inserted through the nose or
mouth into the trachea, by which oxygen, anesthetic gases, and/or
volatile anesthetics are delivered.
5. Laparoscopic Surgery - Intra-abdominal surgery performed through small
incisions with the use of laparoscopic instruments. These are surgical
instruments that include a camera that transmits the image inside the
body cavity by allowing the surgeon to guide the surgical instruments and
perform the procedure.
6. Neuromuscular iunction - The area between the ends of myelinated nerve
fibers and it's corresponding skeletal muscle.
7. Outpatient - A non-hospitalized patient who receives same day medical
treatment, is discharged less than 24 hours following admission, and then
returns home for convalescence.
8. Postoperative myalgia - muscle soreness that occurs after surgery. It is
best described as the feeling one gets after a period of aggressive,
physical exercise.
Research Design, Sample, and Setting
After approval was obtained from the lnvestigational Review Board (I RB)
committees at the University of Tennessee Medical Center-Knoxville and the
University of Tennessee in Knoxville, this prospective, randomized, double-blind
study was carried out as a pilot study on 15 subjects who met the requirements
of the ASA PSC I and/or ASA PSC II (Appendix A). The convenience sample
was selected from all adult outpatients who were listed on the daily surgical
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schedule for laparoscopic surgery at a Level I Adult and Pediatric Trauma Center
in the Southeast United States. The entire investigation took place on 2-North in
the main operating room surgical suites.

Inclusion and Exclusion Criteria
All subjects met the fol lowing inclusion criteria in order to be enrolled in the
study. These criteria included the fol lowing:
1 . Subjects between 1 8 - 50 years of age, as postoperative myalgia is
shown to be most prominent in this age group.
2. Subjects requiring elective, outpatient laparoscopic surgery under general
endotracheal anesthesia, as this helped to eliminate surgical incisional
pain.
3. Subjects with a body mass index (BMI) between 1 8 - 30, as subjects less
than 1 8 may have experienced weakness from a pretreatment dose of
nondepolarizing agent (atracurium).
4. ASA PSC of I or II, as sickly subjects (ASA PCS's > II) have increased
reasons to experience postoperative myalgia.
5. Ambulatory ( outpatient) subjects only, as these subjects would have been
expected to exhibit the most postoperative myalgia.
Subjects were assessed to determine if any exclusion criteria applied to them.
If so, they were not enrolled in the study. Exclusion criteria included the
following:
1 . Subjects not meeting inclusion criteria as described above.

2. Subjects' known to be pregnant, as it has been shown that pregnancy
decreases the incidence of postoperative myalgia.
3. Subjects with co-existing disease states, as they would have fallen into an
ASA PSC level of greater than II.
4. Subjects who were non-ambulatory, bedridden, or wheelchair bound, as
SCh may have been contraindicated.
5. Subjects who experience shivering upon emergence, as this alone could
have caused postoperative myalgia.
6. Subjects who did not have access to a telephone, as follow up calls would
have not been possible.
7. Subjects younger than 18, as informed consent would have been a
parental decision.
8. Subjects older than 50, as $Ch-induced myalgias are reported less
commonly in this group.
9. Subjects allergic to any of the study medications, or medications
employed in the standard study plan (Appendix B).
10. Subjects with any conditions that would be contraindicated by the
administration of any drug within the standard plan (e.g. Malignant
Hyperthermia, neuromuscular disorders, or myofascial pain syndromes).
11. Any subject who was unable to give full voluntary and informed consent.
12. Any subject who received narcotic reversals, such as narcan.
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Informed Consent
Informed consent (Appendix C) was obtained upon completion of the
preoperative interview and determination that the subject met inclusion criteria.
The use of this consent had been approved by the IRB's of both the University of
Tennessee Medical Center-Knoxville, and the University of Tennessee, Knoxville
prior to the initiation of the study (Appendix D). The study �as explained in terms
understandable to the subject, and the subject was given sufficient time to
consider participation prior to providing consent. Subjects were ensured that
they would not be treated differently, regardless of their decision concerning
participation. Those who agreed to participate in the study were informed that, if
at anytime they would better be served by being withdrawn from the study, the
researcher would do so immediately and continue to provide any and all
intervention that was required to safely care for them.
Study Protocol
Preoperatively, all subjects were premedicated with midazolam 0.025 mg/kg
and an appropriate antibiotic as requested by the surgeon. Subjects were
assigned by pharmacy to one of the following three double-blinded study groups
by use of computer generated randomization.
1. Group A was pretreated with atracurium 0.05 mg/kg intravenously (IV)
prior to the administration of 1.5 mg/kg IV of SCh.
2. Group B received 1.5 mg/kg of lidocaine prior to the administration of 1.5
mg/kg of SCh.
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3. Group C received both pretreatment medications at the above indicated
doses prior to the administration of 1.5 mg/kg IV of SCh.
It was decided by the researcher to avoid a control group since many studies
indicate that a 50% incidence of postoperative myalgia can be expected from
the administration of SCh. In addition, although the literature was not clear on
the effectiveness of pretreatment when SCh is utilized, depriving subjects of a
medication that might be of benefit by reducing postoperative discomfort was
not ethically acceptable to this author.
The following study protocol was utilized on all groups:
1. After the researcher obtained informed consent, the subject was
transported to the operating room and positioned on the operating table
appropriately for the surgical procedure.
2. Standard ASA monitoring was utilized (Appendix E).
3. Pre-oxygenation was obtained with 100% oxygen for 2 minutes or 5 vital
capacity breaths.
4. The pretreatment drug was given along with fentanyl 1.5 mcg/kg. (This
dose of fentanyl was given to blunt stimulation from laryngoscopy and
has not been demonstrated to affect myalgias in previous investigations).
5. Five minutes after the administration of the pretreatment drug an
appropriate induction dose of propofol (2-2.5 mg/kg IV) was given for
induction.
6. After complete muscle relaxation was verified, (0/4 twitches following
ulnar nerve stimulation via cutaneous electrodes), tracheal intubation was
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performed and endotracheal tube placement was verified by standard
methods.
7. Anesthesia was maintained with oxygen, and air or nitrous oxide, and by
titrating sevoflurane 0.6%-5% to hemodynamic stability and a surgical
level of anesthesia. The Bispectral Index (BIS) monitor was utilized as an
adjunctive monitor to help assess the subject's level of anesthetic depth.
8. If the subject's blood pressure and heart rate fluctuated (Appendix F)
(increased or decreased) greater than 20% of base line, then
vasodilators, vasopressors, inotropes, or chronotropes were administered
as appropriate for the situation. If the subject failed to respond, they were
eliminated from this study and further appropriate treatment was
instituted.
9. The following drugs were administered as their need arose: narcotics,
(fentanyl 2-10 mcg/kg), nondepolarizing muscle relaxants, antiemetics,
steroids, antibiotics, vasoactive drugs, and muscle relaxant reversals.
These medications were not part of the study protocol, but are routinely
employed in the anesthetized patient. (See Appendix B for this study's
formulary doses and adverse effects of drugs).
10. After completion of the surgery, anesthesia was discontinued. The
subject was given 100% oxygen to breathe. They were extubated when
extubation criteria were met (Appendix G). Following extubation, the
subject was taken to the post-anesthesia recovery room. If the subject's
nurse observed any postoperative shivering, it was documented on the
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PMES in Appendix H. (Such subjects were withdrawn from the study, as
shivering has been shown to cause myalgias).
1 1 . All subjects were contacted 24, 48, and 72 hours postoperatively by
telephone and asked the questions listed on the PMS (Appendix I). The
researcher then rated and recorded the level of myalgias using the PMES
(Appendix H).
As described, pre-treatment medications in all three groups were
administered to subjects using a double-blind format. The surgical pharmacy
randomly assigned subjects to one of the three study groups by computerized,
random selection. Syringes of study medications were labeled with numbers
(from 1 -1 5) by the pharmacy staff for each patient enrolled in the study. The
pharmacy was the only provider who knew which patient received which study
medication prior to completion of the study. The pharmacy staff was instructed
to disclose this information if and only when the following occurred:
1 . All data had been collected.
2. The study was complete or it was closed.
3. Lastly, in the case that it became necessary to know what medications
had been given, as in the case of an allergic reaction.
Every pretreatment medication came in a syringe that contained the same
volume amount, regardless of the exact medication. This was done so the
researcher in no way could identify which pretreatment medication was given.
Dosages of all medications were calculated based on per kg of body weight by
the pharmacy prior to anesthetic administration. At the end of the study, the
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drugs were identified to conclude whether there was a difference between the
pretreatment groups with respect to comparison of one another. The same
researcher was used to gather all postoperative information regarding myalgia.
This data was analyzed after the completion of data collection.
All subjects were assigned a number once enrolled in the study. Subjects
were sequentially numbered 1-15. A Demographic Data Sheet (See Appendix
J), served as the master enrollment list, and was maintained on all subjects who
agreed to participate in the study. This data sheet contained the following
information:
1. Name
2. Phone Number
3. Subject number ( 1-15)
4. ASA Class
5. Weight in Kg
6. Height in inches
7. Gender
8. Smoking history
9. Preoperative narcotic and NASID use (dose and duration)
10. Postoperative narcotic and NASID use (dose & duration)
For reasons related to postoperative data collection, it was necessary to
maintain the subject's name and telephone number. However, subjects were
not to be identified by any method other than on the Demographic Data Sheet,
unless it became necessary for the safety of the subject as in the case of an
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allergic reaction or unstable hemodynamics. As mentioned previously, such
subjects would have been removed from the study. In these instances, the
double-blinded protocol medication would have been revealed so as to provide
the most appropriate and prompt intervention possible.
Instrumentation
The PMS (Appendix I) is a tool that was utilized by the researcher to confirm
the patient was experiencing postoperative myalgia, as opposed to some other
type of postoperative surgical discomfort. The PMS is a 14-question survey that
determines the type, location, and amount of pain being experienced.
Additionally, it inquired about the subject's activity level, as well as any
treatments they attempted to help alleviate the muscular soreness. This survey
has only been utilized in one previous study, which was discovered in the body
of associated literature: The works of Mikat-Stevens, Sukhani, Pappas, Fluder,
Kleinman, and Stevens (2000). Therefore, the PMS has no proven validity or
reliability. Its use in this study is being justified by the following reasoning.
Many past studies on the subject of SCh use and postoperative myalgia have
failed to carefully distinguish between myalgia and surgical discomfort. The
PMS aids the investigator in establishing this distinction, which was considered
by this author to be of fundamental significance to the purpose of this
investigation. Utilizing two tools within this study helped to assure, with greater
confidence, that proper assessment of the type of postoperative pain was
distinguished allowing for the overall study results to be truly reflective of
postoperative myalgia as it related to perioperative SCh administration.
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The PMES (Appendix H) is a four-point ordinal scale that measures the
severity of postoperative myalgia from zero to three, where [O] indicates
absence of pain other than characteristic surgical gas, [1] indicates mild muscle
stiffness or pains, when specifically asked about, in the nape of the neck, or in
shoulders and lower chest on deep breathing, [2] indicates moderate muscle
stiffness and pains spontaneously complained of by the patient [3] indicates
severe, incapacitating, generalized muscle stiffness or pain. Although the
PMES, or very similar scale, has been used in several previous studies of
comparable nature and scope as this one, this scale had no proven reliability or
validity. However, numerous respected scientists have accepted this instrument
as a valid and reliable measure of postoperative myalgia in subjects following
the administration of SCh with general anesthesia. These same authors have
utilized this instrument for the purpose it was used in this author's investigation.
Such studies have had similar scope and intent as the current one (Mingus,
Herlich, & Eisenkraft, 1990; Mcloughlin, Elliot, McCarthy, Mirakhur, 1992;
Raman & San, 1 997). All such, authors have been published in a variety of
respected and refereed scientific medical journals including: Anaesthesia and
the Canadian Journal of Anaesthesia. Consequently, since there were no
alternative tools that existed which had a proven higher index of validity or
reliability, this author chose to utilize these two tools in the current study in
hopes of obtaining a more accurate picture of the phenomena of postoperative
myalgia in relation to SCh administration. The goal of using these two tools was
to accurately measure the occurrence and severity of postoperative myalgia
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following SCh administration subsequent to the pretreatment of atracurium,
lidocaine, or the combination of the two. Since it was important to maintain
consistency and provide reliable measurements of postoperative myalgia, the
same researcher administered the survey and rated the severity of soreness to
study subjects for up to 72 hours postoperatively (See protocol #11).
Data Analysis
Comparison of the mean scores of the three study groups would traditionally
have been performed by analysis of variance (ANOVA) utilizing parametric
testing. However, this statistical application would have required a specific
distribution of the mean and variance. Testing of the PMES lies within a gray
area, and such, a distribution could not be assumed. Therefore, a
nonparametric ANOVA with post-hoc analysis was employed. Specifically, the
Kruskal-Wallis, a test for two or more independent samples, and the Bonferroni
test utilizing a significance level of p<=0.05 was employed.
The Kruskal-Wallis test calculates results based on the sums of the ranks of
the combined groups in the PMES. For example, the scores for each variable
(0, 1, 2, 3) was ranked, and the mean ranks for the variables were compared. If
a significant difference was found (p<= 0.05) a post-hoc analysis utilizing the
Bonferroni method was planned to be employed to identify where the difference
occurred. Because this method is more sensitive in small comparisons, it was
utilized in this pilot study of 15 subjects. Such methods were utilized not only to
determine which pretreatment medication(s) were significantly effective in
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reducing postoperative myalgia, but also to determine which postoperative day
subjects experienced the most/least myalgia.
Assumptions
The basic assumptions made regarding this study were as follows:
1. The PMS and PMES were predictive and accurate instruments for
measuring postoperative myalgia.
2. The population sample was representative of a random sample.
3. The researcher was consistent at determining if the pain was myalgia
verses surgical discomfort.
4. The researcher consistently rated the postoperative myalgia as described
by the patient in the PMES.
Study Limitations
1. The review of the literature may not have been wholly reflective of reality.
2. There may have been unanticipated individual varying responses to the
prescribed anesthetic plan.
3. There may have been sources of error concerning myalgia during data
collection. However, this study attempted to take this into account by:
(A) utilizing two tools that had been used significantly within the
anesthesia literature, and (B) having the same researcher gather/rate the
levels of myalgia.
4. In regards to conclusions, to using the pretreatment medications of
atracurium, lidocaine, or a combination of medications may not be able to
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be generalizable to larger populations because of this pilot study's small
sample size.
5. Because the average incidence of SCh-induced postoperative myalgia is
only 50% according to the literature, the benefits of a control group may
have been useful for comparison.
6. Neither the PMS nor PMES being utilized to measure postoperative
myalgia has undergone extensive psychometric testing for validity or.
reliability.
7. This study made no attempt to control for the amount or type of
medications that were prescribed and utilized by the subject
preoperatively. Data on subject use of medications preoperatively,
however, was collected.
Specific Risks and Protection Measures for Human Subjects
All medications utilized for this study have side effects that could have
caused adverse reactions (Appendix 8). Although rare, some possible side
effects that could have occurred included nausea, vomiting, sedation, prolonged
muscle weakness, high potassium, increased body temperature, and seizures.
Such reactions may have occurred in subjects receiving these drugs in the
course of anesthesia regardless of whether or not the patient was participating
in the study. Therefore, although there were associated risks to subjects in
relation to their participation in this study, the potential for additional physical,
psychological, social, legal, or other risks were estimated to be no greater than
those compared to surgical subjects who did not enroll in this study and who
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had received the same anesthetic medications and interventions commonly
utilized in acceptable anesthetic practice. No drug or procedure in this study
was proposed to be used in any manner that was outside of the normal
anesthetic standard of care or acceptable patient care practice. Consequently,
no additional amount of risk for injury was predicted for any subjects who agreed
to participate in the study.
Anonymity and confidentiality of data collected was indefinitely maintained.
During the data collection phase, and at all times following this period, all data
was under the direct supervision and control of the researcher, or an authorized
assistant. Each subject was assigned a number (not the medical record or social
security number), and other than the Demographic Data Sheet/Master Subject
List (for purposes of follow up call and data collection), no linkage between the
subject and subject number was made. Storage of this information will be
maintained in a locked area within the anesthesia department at the University of
Tennessee Medical Center-Knoxvil le for a period of five years following the
study. At the conclusion of this time period, the records wil l be destroyed by
means of shredding.
Although such patient data safeguards, as above, are included in the design
of this study, patient data may be released through publication of research
findings in such a fashion that subjects may be able to identify themselves with
their data. This remote possibility is no greater for this study than any other
research project. Lastly, upon postoperative follow-up at 24, 48, and 72 hours,
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the PMS (Appendix I) was utilized to assure that no physical, psychological, or
social damage occurred as a result of this study.
Study Benefits
In conclusion, there are currently no proven therapeutic alternatives to the
treatment of postoperative myalgia. Many studies have undertaken the task to
examine this concept. However, to date, study results have been inconclusive in
yielding definitive results. Therefore, potential benefits of this study, which
established the justification for conducting this investigation, included the
following:
1. A more comfortable recovery.
2. Decreases in the loss of productivity through earlier return to preoperative
level of functioning, with respect to the individual subject's baseline in
activities of daily living related to decreased myalgia postoperatively.
3. Fewer returns to the emergency room related to postoperative discomfort
and concern over the source of discomfort.
4. The potential for a decreased need of postoperative pain medication.
5. The potential for decreases in health care expenditures related to poor
resource utilization.
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Chapter IV
Results
This chapter presents the results of this author's pilot study, which was
designed to compare the efficacy of atracurium, lidocaine, and the combination of
the two therapies on the outcome of postoperative myalgia following the
administration of SCh during general anesthesia. The purpose of this
investigation was not to document statistical significance in relation to
premedication efficacy for such a small pilot population, but rather to determine
the overall feasibility of conducting a larger study. Additionally, a secondary
purpose of this pilot study was to look for trends within this population that might
contribute to outcome and indicate clinical importance with need for further and
future investigation.
As this study has shown, besides the use of SCh, other influential factors can
contribute to postoperative myalgia including ASA PSC, history of cigarette
smoking, surgical position, the use of pre-surgical pain medications and surgical
type. Therefore, the purpose of this chapter is two-fold: First to provide the
outcome of differing pretreatment groups on postoperative myalgia, and second
to offer descriptive statistics about the population, the above influential factors,
and their interactions with the pretreatment groups. Through the use of these
results, this author contends that further support and investigation is indeed
justified and that the conduction of a larger study on SCh use and myalgia is
warranted.
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Descriptive Statistics
The study population was comprised of 1 5 subjects undergoing elective
laparoscopic surgery requiring general anesthesia with the use of SCh. Of the
1 5 enrolled in the study, two were excluded. One subject was excluded due to a
change in intraoperative procedure, and the other subject was excluded because
of the unforeseen use of a laryngeal-tracheal anesthetic (LTA) that contained
lidocaine. Use of this intervention could have potentially influenced the observed
results and therefore altered the outcome of the study. Of the remaining 1 3
subjects, gender distribution included 1 2 (92%) females and one male (8%) who
ranged in age from 21 to 46, with a mean age of 33. All subjects were healthy
with eight (62%) having an ASA PSC of I, and 5 (38%) being an ASA PSC of I I .
Two subjects (1 5%) were smokers, and eight (62%) were taking nonsteroidal or
narcotic medications for pain prior to surgical intervention.
The 1 3 subjects were placed in one of three computer randomized
pretreatment groups: (1 ) atracurium 0.05 mg/kg, (2) lidocaine 1 .5 mg/kg, (3) or
a combination of atracurium 0.05 mg/kg and lidocaine 1 .5 mg/kg. Because past
studies have indicated that there is a 50% incidence in SCh postoperative
myalgia without any pretreatment, this author felt it unethical to include such a
group for control (Wong & Chung, 2000). Therefore, since the main purpose of
the study was to determine the feasibility of instituting the scientific investigation,
�nd also whether these small pilot groups would follow the recurring trends that
are found within today's research literature, lack of a control group was not of
issue to this author or other investigators performing this study.
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Pretreatment Group Efficacy
After one of the researchers obtained subject consent, a hospital pharmacist
was responsible for keeping track of the subjects computerized randomized
classification, as well as compounding and preparing the correct study drug
regimen for administration. As a result, the subjects were well distributed in the
three pretreatment groups with five subjects (38%) in the atracurium group, four
(31%) in the lidocaine group, and four (31%) in the combination atracurium and
lidocaine group. In terms of pain intensity, the results from the subjects in each
pretreatment group were then compared to one another each day (for a total of
three days). This author utilized the Kruskal-Wallis test, a nonparametric version
of the one-way analysis of variance for independent samples, which was
calculated based on rank sums of the pretreatment groups for comparison
between the pretreatment groups. It is important to note that intensity and the
number of participants experiencing pain over the course of three days is
different. Table 2 and Figure 2 describes and illustrates the percent of each
group experiencing pain, while the rest of this section predominantly refers to
intensity of pain.
A comparison of the mean scores of intensity of pain for the first postoperative
day is presented in Table 3 and illustrated in Figure 3. No significant difference
was found between any of the pretreatment groups. In other words, statistically
speaking, none of the pretreatment medications exhibited any increased ability to
prevent postoperative myalgia when compared to the others. However, as
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Table 2.
Postoperative Myalgia: Percent of each Pretreatment Group per Day
Day 1

Day 2

Day 3

Atracurium

60%

40%

20%

Lidocaine

50%

50%

50%

Combination

50%

50%

50%

60
50
40

' G:J Atracurium
■ Lidocaine
ISi Combination

30
20
10

Day 1

Day 2

Day 3

Figure 2.
Postoperative Myalgia: Percent of each Pretreatment Group per Day
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Table 3.
Pain Comparison of Pretreatment Groups on Postoperative Day One
Mean
Atracurium

1 .20

Standard
Deviation
1 .30

Lidocaine

1.00

1. 15

NS - 0.858

22 - 30

27

Combination

. 75

0.96

NS - 0.858

21 - 4 1

31

Significance

(Kruskal-Wallis)

NS - 0.858

Age Range Mean
Age
32 - 46
41

* = Significant difference at the a = 0.05 level
NS = Not Significant

1 .2

1
0.8

------------4 e Atracurium

0.6

■ Lidocaine

� Combination I

0.4
0.2
Mean

Significance

* = Significant difference at the a = 0.05 level
Figure 3.
Pain Comparison of Pretreatment Groups on Postoperative Day One
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mentioned above, the atracurium group was found to have the most
postoperative myalgia on day 1, with 60% of subjects having pain, followed by
50% within both the lidocaine and combination groups. Although the same
percentage of subjects complained of pain in the latter two groups, the
combination group was found to have reported less intense pain scores
regarding postoperative myalgia on day one, in comparison to the subjects in the
atracurium and lidocaine group. This was a finding that is well supported within
the literature (Raman & San, 1987).
Table 4 and Figure 4 describes and illustrates the comparison of the mean
scores for intensity of postoperative pain in the three pretreatment groups on
postoperative day two. Like the first postoperative day, no significant difference
was found among any of the pretreatment groups in regards to the intensity of
reported postoperative myalgia. As above, although the number of subjects
complaining of pain decreased from the first day, the atracurium group (40%)
continued to experience the most intense postoperative pain. Although the
lidocaine group remained at 50% of subjects experiencing pain, the intensity
reported by these subjects was less than the subjects in the atracurium group.
Lastly, in the combination lidocaine/atracurium group, 50% of subjects
complaining of pain did not exhibit any decrease in the intensity of postoperative
pain from day one. This was unlike the subjects in the atracurium and lidocaine
groups. This was a surprising finding since this had not been reported in the
literature (Melnick, Chalasani, Uy, Phitayakorn, Mallett, & Rudy,
1987) .
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Table 4.
Pain Comparison of Pretreatment Groups on Postoperative Day Two

Atracurium

0.80

Standard
Deviation
1. 10

Lidocaine

0.75

0.96

NS-1.000

22-30

27

Combination

0.75

0.96

NS-1.000

21 - 4 1

31

Mean

Significance
NS - 1.000

Age Range Mean
Age
32 - 46
41

(Kruskal-Wallis)

* = Significant difference at the a = 0.05 level
NS = Not Significant

. � Atracurium
I Lidocaine

■

� Combination

Mean

Significance

• = Significant difference at the a = 0.05 level
Figure 4.
Pain Comparison of Pretreatment Groups on Postoperative Day Two
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As described in Table 5 and illustrated in Figure 5, there was no significant
differences in terms of intensity of postoperative myalgia demonstrated between
the three pretreatment groups on postoperative day three. Although the
atracurium group had started out with the most pain (60%) on day one, it had
gradually decreased each consecutive day and actually ended up reporting the
least amount (20%) of pain by postoperative day three. One subject, however,
continued to experience pain on postoperative day number three, and reported
the intensity of their pain as moderate.
In terms of the amount of pain, 50% of the subjects in the lidocaine group, on
day three reported the same amount of pain as the atracurium group in terms of
intensity. Although this group started out reporting mid-range levels of pain
intensity on day one (between atracurium and the combination group) and
decreased slightly on day two, they did not improve by day three. Again, this
was an interesting finding that is not congruent with the current literature of
Melnick and associates.
Additionally, as mentioned earlier in this chapter, the subjects in the
combination group of atracurium and lidocaine started out reporting the least
amount of intense pain. However, the scores reported by the subjects in this
group on postoperative day two was exactly the same as on postoperative day
one. Although, subjects within the combination group continued to improve in
terms of pain intensity, they surprisingly reported pain scores that fell between
the scores reported by the subjects in the atracurium and lidocaine groups on
day three. This too, was a finding that differed from current literature.
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Table 5.
Pain Comparison of Pretreatment Groups on Postoperative Day Three

Atracurium

0.40

Standard
Deviation
0.89

Lidocaine

0.75

Combination

0.50

Mean

Significance

(Kruskal-Wallis)

Age Range

· NS-0.725

32 - 46

0.96

NS-0.725

22 - 30

0.58

NS-0.725

21 - 4 1

* = Significant difference at the a = 0.05 level
NS = Not Significant

1
0.8

0.6

i m Atracuriurn
Lidocaine

,■

0.4

ISi Combination

0.2
0

Mean

Significance

* = Significant difference at the a = 0. 05 level
Figure 5.
Pain Comparison of Pretreatment Groups on Postoperative Day Three
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Additionally, on day three the combination lidocaine/atracurium group continued
to exhibit 50% of its subjects complaining of postoperative myalgia.
ASA Physical Status Classification and Postoperative Myalgia
As is evident from examining the results listed in Table 6 and illustrated in
Figure 6, ASA PSC did not have a statistical significance on postoperative
myalgia. This is not unexpected due to small sample size. However, some
potentially interesting clinical aspects arise from comparing ASA PSC to
postoperative myalgia. Within this pilot study, 62% of subjects were classified
as ASA PSC I, while 38% were ASA PSC II. Of the eight subjects classified as
ASA PSC I, three (37.5%) were in the atracurium group, four (50%) were in the
lidocaine group, and one ( 1 2.5%) was in the combination group. Within the ASA
PSC I group, three individuals (37.5%) complained of pain. The lidocaine group
exhibited the most pain during day one (50%), followed by the atracurium group
(33% ). The combination lidocaine/atracurium group in this class (ASA PSC I)
remained pain free on day one. Additionally, as an experienced anesthesia
practitioner might anticipate for this collection of subjects, the lidocaine group
reported the highest pain scores, with two individuals declaring their pain as
moderate on the first postoperative day.
On day two and three, only two subjects (25%) exhibited pain within this ASA
PSC I sub classification. On both days, these were subjects from the lidocaine
group and they rated their pain scores as mild and moderate.
The ASA PSC II group contained five (38%) subjects. Four (80%) of these
subjects complained of pain on the first postoperative day. This was a much
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Table 6.
ASA Physical Status Classification and Postoperative Myalgia
Day 1
Pain
0.4 1

ASA

Significance Day 2
(Kruskal-wa11is)
pain
NS
0. 15

Significance Day 3
(Kruskai-Wallis)
pain
0.45
NS

Significance
(Kruskal-Wallis)

NS

• = Significant difference at the a = 0.05 level
NS = Not Significant

0.5
0.4
0.3

53 Atracurtum

■ Lidocaine
■ Combination

0.2
0.1
Mean

Significance

• = Significant difference at the a = 0.05 level
Figure 6.
ASA Physical Status Classification and Postoperative Myalgia
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higher incidence when compared to the ASA PSC I group, where only 37.5%
reported pain. Additionally, the ASA PSC II group did not have any subjects in
the lidocaine group. Therefore, comparisons between the pretreatment groups
and ASA PCS I and II was limited since the ASA PSC II group did not contain
any subjects in one of the pretreatment groups. This finding is interesting when
one considers the fact that the lidocaine group reported the highest pain scores
on all three days in the ASA PSC I group. Therefore, this leads this author to
postulate that perhaps subjects classified as an ASA PSC II may have a higher
incidence of postoperative myalgia when SCh is used in conjunction with a
general anesthetic.
When further examining this group (ASA PSC II), two subjects (40%) were in
the atracurium group, while three subjects (60%) were in the combination group.
All subjects (100%) complained of pain in the atracurium group with rated pain
scores of moderate and severe on postoperative day one, while two subjects
(67%) in the combination group complained of pain with ratings of mild to
moderate. Following progression to postoperative day two, the amount and
intensity of pain for the combination lidocaine/atracurium group remained the
same on day two as reported on day one. The amount and intensity of pain
scores for the atracurium group improved, as all subjects rated their pain as
moderate. By day three, both groups had improved in amount and intensity of
pain. The atracurium group had only one subject (50%) complaining of moderate
pain and the two subjects (67%) within the combination atracurium/lidocaine
group reported only mild pain ratings.
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Smoking History and Postoperative Myalgia
Of the 13 subjects, only two (15%) were smokers. Both subjects had
significant smoking histories of one to two packs of cigarettes consumed per day
for five years. Interestingly enough, postoperative pain studies revealed that
these individuals had higher pain scores that lasted (and did not improve) for the
duration of the third postoperative day. Table 7 and Figure 7 displays and
illustrates this data. - In addition, further analysis revealed that each of these two
subjects received the combination pretreatment.
Recalling the pattern of this group (which started out reporting the least
amount of intense pain, but increased to an average amount of intense pain)
suggests that smoking may be an influential factor responsible for increasing
postoperative pain in subjects wtio receive SCh. However, as the following data
will show, further analysis also revealed other factors that may have contributed
to this outcome: Lithotomy position during anesthesia, subjects self
administering medications prior to surgical intervention, and the fact that both
individuals had diagnostic laparoscopic procedures.
Nonsmokers (85%) were members of all three pretreatment groups. They
were found to demonstrate the general population trends that have been
previously noted within each pretreatment group. The atracurium group had the
most number of subjects and 60% of these subjects reported the most intense,
severe pain on the fi rst postoperative day. The lidocaine group had a 50%
incidence of moderate pain, and surprisingly, the combination group did not
report any pain.
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Table 7.
Smokers and Nonsmokers: Postoperative Pain
Day 1

Mean pain
score

Standard
Deviation

Day 2

Mean pain
score

Standard
Deviation

Day 3

Mean pain
score

Standard
Deviation

Nonsmoker 0.91

1.14

0.64

0.92

0.45

0.82

1 .50

0.71

1 .50

0.71

1 .50

0.71

Smoker

1.6
1.4
1.2
1
0.8
0.6

·�-�--

�--

Day 1

■ Nonsmoker
■ Smoker

Day 2

Day 3

Figure 7.
Smokers and Nonsmokers: Postoperative Pain
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For postoperative days two and three, reported levels of pain in the atracurium
group declined in frequency as well as intensity. 40% of the subjects reported
with moderate pain and 20% of the subjects reported with mild pain. The
lidocaine group (50%) continued to repeat the same frequency and intensity with
mild and moderate pain reported on both days. Again, ironically, the combination
atracurium/lidocaine group reported being free from pain for both days.
Surgical Position
This study involved the enrollment of subjects who were having surgical
procedures that required they be placed in either the supine or the lithotomy
position. Although not statistically significant, as indicated by Table 8 and
illustrated by Figure 8, when subject position is broken down and evaluated
separately it does appear to have some clinical significance in reference-to
postoperative pain. Eight (61.5%) subjects were in lithotomy, while five subjects
(38.5%) were in supine position.
As Table 9 and Figure 9 demonstrate, those subjects in lithotomy position did
experience more postoperative myalgia for all three days as compared to those
subjects who remained in supine position. These findings lead this author to
question if lithotomy position may have been a contributing factor to
postoperative myalgia in these subjects.
There were subjects enrolled in all three pretreatment groups who were
placed in lithotomy or supine positions. However, when examining only subjects
in the supine position, only one individual complained of pain for all three
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Table 8.
Surgical Position and Postoperative Myalgia
Day 1
Pain
Position 0.28

Significance Day 2
Pa in
NS
0. 1 9

(Kruskal-Wallace)

Significance Day 3
(Kruskal-Wallace)
Pain
0.33
NS

Significance
(Kruskal-Wallace)

NS

* = Significant difference at the a = 0.05 level
NS = Not Significant

I■
Day 1

Day 2

Day 3

Figure 8.
Surgical Position and Postoperative Myalgia
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Position

I

Table 9.
Surgical Position and Postoperative Myalgia: Lithotomy and Supine
Position
Lithotomy

Day 1
Mean
1 .38

Standard
Deviation
1.06

Day 2
Mean
1 . 13

Standard
Deviation
0.99

Day 3
Mean
0.63

Standard
Deviation
0.74

Supine

0.40

0.89

0.20

0.45

0.40

0.89

1A
1.2
1

■

0.8
0.6

l'.9 Suplne

OA
0.2

0

Llthotorny

Day 1

Day 2

Day 3

Figure 9.
Surgical Position and Postoperative Myalgia: Lithotomy and Supine
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postoperative days. This subject was in the lidocaine only group and reported
moderate pain on postoperative day one, mild pain on the second day
postoperatively, and moderate pain by the third postoperative day.
Of subjects who were positioned in lithotomy, patterns of postoperative pain
somewhat followed the general trends as detailed previously in this chapter for
the pretreatment groups. The atracurium group started out with the most
subjects (75%) complaining of pain and subjects who complained of the greatest
intensity of pain. Over the three days of postoperative data collection, subjects
complaining of pain gradually decreased to 50% and 25% by days two and three
respectively. Subjects reported pain intensity did not diminish over the three
days of postoperative data collection.
With respect to the number of subjects experiencing postoperative pain in the
lithotomy position, study results indicated that the lidocaine only group ( 1 00%)
and combination group (66%) reported similar discomfort for all three
postoperative days. Both groups also reported the same pain intensity scores for
the first two postoperative days, with lidocaine (1 subject) being moderate, and
the combination group (3 subjects) being mild and moderate. By the third
postoperative day, both groups also exhibited a decline in pain with lidocaine
becoming mild, and the subjects in the combination group also reporting their
pain as being only mild.
Pain Medication use Prior to Surgical Intervention and Postoperative Myalgia
Again, as indicated by Table 1 0 and Figure 1 0, statistical significance between
the use of medication and postoperative myalgia was not demonstrated
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Table 10.
Premedication and Postoperative Myalgia
Day 1
Pain
Medication 0.84

Significance Day 2
(Krus1<a1-wa11is)
Pain
NS
0.61

• = Significant difference at the a
NS = Not Significant

" I1■1
• - 11
. ,. --

=

Day 1

Significance

(Kruskal-Wallis)

NS

0.05 level

I■

I

I

Significance Day 3
Pain
NS
0.20

(Kruskal-Wallis)

Day 2

Day 3

Figure 10.
Premedication and Postoperative Myalgia
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Medication

I

due to small sample size. However, when analyzing this group independently,
there does appear to be at least some clinical significance. Fifty-four percent (7
subjects) were taking some type of pain med ication (either nonsteroidal or
narcotics) prior to surgical intervention .
As Table 1 1 and Figure 1 1 wil l ind icate, these individ uals reported hig her
postoperative pain scores for all three days, than d id those who were not taking
any type of pain medication preoperatively . Additionally, subjects who did not
report preoperative pain medication use required less postoperative pain
medication as compared to subjects who reported taking pain medications
preoperatively. Althoug h the data was not collected, it would be interesting to
find out how long such individuals had been taking pain medications prior to
surgery in order to address: (1 ) Is there a greater incidence of postoperative
myalgia in those who suffer from chronic pain as opposed to those with acute
pain? And (2) how would this affect postoperative pain management?
Obviously, these are questions to explore for future study.
Type of Surgery and Postoperative Myalgia
The population for this pilot study involved only laparoscopic surgeries in an
effort to distinguish postoperative myalgia from incisional pain. Therefore, this
study involved the fol lowing various types of laparoscopic procedures:
Diagnostic laparoscopic procedures (62%), cholecystectomies ( 1 5%), tubal
ligations (1 5%) and herniorrhaphanies (8%) . However, because of the limited
population, not all surgical types were represented within each study g roup. As
previously discussed in this chapter, statistical analysis of each surg ical
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Table 1 1 .
Premedication Prior to Surgical Intervention and Postoperative Myalgia

Premed
use
No
Premed
use

Day 1
Mean
1 .14

Standard
Deviation
1 .22

Day 2
Mean
1 .00

Standard
Deviation
1 .00

. Day 3
Mean
0.71

Standard
Deviation
0.76

0.83

0.98

0.50

0.84

0.33

0.82

1 .2
1

0.8

■ Premed use

0.6

, � No Premed use

0.2
0

Day 1

Day 2

Day 3

Figure 1 1 .
Premedication Prior to Surgical Intervention and Postoperative Myalgia
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procedure in groups containing adequate numbers of subjects could yield
significant statistical results. Since this was a pilot study, determining statistical
significance was not a goal. Therefore, this section will only provide descriptive
data on those subjects that agreed to participate in the study. As the data Table
12 and Figure 12 illustrates, there was no statistical significance found between
surgical type and postoperative myalgia.
Diagnostic Laparoscopic Procedures
Subjects undergoing diagnostic laparoscopic procedures were enrolled in the
atracurium group (37.5%), lidocaine group (25%), and a combination
atracurium/lidocaine group (37.5%). On postoperative day one six subjects
(75%) having diagnostic procedures complained of pain, With pain scores ranging
from mild to severe. All three subjects (100%) within the atracurium group had
pain, reporting it as mild, moderate, or severe. On this same day, 50% (1
subject) of the lidocaine group had moderate pain, and 66% (2 subjects) of the
combination group had both mild and moderate pain.
For postoperative day two, only five (63%) subjects complained of pain after a
laparoscopic, diagnostic procedure. The lidocaine and combination groups did
not differ in amount or rating of pain from day one. The only change came in the
atracurium group. Here, only 2 subjects (66%) complained of pain, both
reporting their pain as moderate. Therefore, it can be said that in this group, one
patient felt better, and another felt worse on postoperative day two.
On the third postoperative day, only four (50%) subjects continued to
complain of myalgia after their diagnostic laparoscopic procedure. These
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Table 1 2.
Surgical Type and Postoperative Myalgia
Day 1
Pain
Surgical 0.33

Type

Significance Day 3
Pain
NS
0.35

Significance Day 2
(Kruska-wa11is)
Pain
NS
0.21

(Kruskal-Wa11is)

Significance

(Krusta.Wallis)

NS

• = Significant difference at the a = 0.05 level
NS = Not Significant

I
Day 1

Day 2

Day 3

Figure 1 2.
Surgical Type and Postoperative Myalgia
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£1 Surgical Type

I

comprised of 33% of the subjects in the atracurium group (1 subject), 50% of the
subjects (1 subject) in the lidocaine group, and 66% of the subjects (2 subjects)
in the combination group. As noted, in terms of percentages in the amount of
pain, no change from day one was observed for the lidocaine group or the
combination atracurium/lidocaine group except that pain was rated as mild in
both groups. Although the greatest percentage of subjects complaining of pain
(mild) were in the combination group, this observation could be deceiving, as the
atracurium group had the worst description of pain (moderate) at the third
postoperative day. Therefore, from a clinical practitioner's perspective, it is
difficult to conclude which pretreatment group demonstrated a superior ability for
preventing SCh-induced postoperative myalgia.
Laparoscopic Cholecystectomies
Laparoscopic Cholecystectomies comprised 15% of the surgical procedures
performed on subjects enrolled in this study. This group was composed of only
two subjects, with one subject representing the atracurium pretreatment group,
and the other subject from the lidocaine pretreatment group. It is interesting to
note that neither subject complained of pain on any of the three monitored
postoperative days. Further analysis revealed that both subjects were female
aged 40 and 41 , nonsmokers, in supine position during anesthesia, and taking
pain medications prior to surgical intervention. Additionally, they were from two
different ASA PSC groups (I and 1 1, respectively). It was ironic that these two
subjects had increased risk factors for postoperative myalgia, such as (1) being
female, (2) being middle-aged, and (3) taking pain medications prior to surgery,
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yet neither exhibited any reported postoperative pain. These results suggest that
other factors, besides the administration of SCh may play a role in the
development of postoperative myalgia.
Laparoscopic Tubal Ligations
Laparoscopic Tubal Ligations comprised 15% of the surgical procedures
performed on subjects who agreed to participate in this study. However, only the
combination atracurium/lidocaine pretreatment group underwent this type of
surgical intervention. Therefore, descriptive analysis of this surgical group
presents inconsistent results at best. For example, on postoperative day one,
one subject reported no pain and the other reported moderate pain. On
postoperative day number two, one subject continued to report no pain, while the
other reported an improvement from moderate to only mild pain. However, on
the last postoperative day, the individual who reported mild pain on day two
digressed to moderate pain. The other subject continued to remain pain free for
all three days.
Further analysis revealed that both subjects were ASA PSC I females, aged
28 and 26 years, nonsmokers, positioned supine during anesthesia, and did not
take any medications prior to surgical intervention. Since these two subjects
were very similar, pretreated with the same pretreatment group, and had very
differing responses to pain, this once again is suggestive that some other
mechanism may contribute to postoperative myalgia in subjects who receive
SCh.
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Laparoscopic Hemiorrhaphanies

Laparoscopic hernia repairs consisted of only 8% ( 1 subject) of the surgical
cases in this study. This subject was a 46 year-old male. He received
atracurium as a pretreatment medication prior to the administration of SCh.
Interestingly enough, he reported no pain for all three postoperative days.
Further analysis revealed he was an ASA PSC I , nonsmoker, in supine position
during anesthesia, and did not take any pain medications prior to surgical
intervention. Thus, other than age, had very few risk factors associated with the
development of postoperative myalgia.
As one can see from these results, many factors can play a role in the
development of postoperative myalgia. This study confirmed several trends,
which have been previously reported within the literature in regards to
postoperative pain and myalgia. These include that the incidence of
postoperative myalgia following SCh administration is: ( 1) Greatest in females,
(2) increased in incidence in those patients closer to age 50, and (3) greater in
subjects who are forced (by necessity of the nature of surgery) to assume
varying positions (other than supine) during the anesthetized period. The results
of this author's study has raised many new potential questions focusing on
issues of: (1) Cigarette smoking, (2) preoperative pain medication utilization prior
to surgical intervention, (3) ASA PSC on postoperative myalgia/pain, and (4) the
effect of the type of surgical intervention in relation to postoperative myalgia.
Obviously, the relationship of SCh with postoperative myalgia warrants further
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study. Most likely many factors including those mentioned above, as well as
others, may be contributing to this complex and poorly understood phenomenon.
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Chapter V
Discussion
Current literature suggests that the average incidence of postoperative
myalgia is approximately 50% for patients that receive SCh without any
pretreatment regimen (Wong & Chung, 2000). Although the relationship between
SCh and myalgia is not well established, this author believes the literature that
supports the theory that pretreatment will provide a protective effect against the
occurrence of postoperative myalgia when SCh is utilized ( Pace, 1990; Raman &
San, 1997). However, as mentioned earlier, determining an efficacious
pretreatment regime was not the goal of this study. Rather, determining
feasibility of conducting a larger study, and documenting trends within a small,
experimental population that might signify clinical significance, warrant the need
for research in this area. Indeed, as the rest of this chapter will describe, this
study provided the basis for the formation of numerous new research questions,
as well as debate the findings of old research questions, regarding the
phenomena of postoperative myalgia attenuation following the use of SCh as a
component of a general anesthetic.
Pretreatment Group Efficacy
Although the exact cause of SCh-induced postoperative myalgia is unknown,
the current standard pretreatment utilizes the administration of a nondepolarizing
agent three minutes prior to SCh administration (Wong & Chung, 2000).
However, many have argued that the use of lidocaine is as effective as
nondepolarizing agents. Additionally, lidocaine does not cause unwanted side
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effects such as undesirable intubating conditions, the need to use higher
amounts of SCh and delayed return of spontaneous respiration (Haldia, Chatterji,
& Kackar, 1974 ). Furthermore, combination therapy utilizing lidocaine and a
nondepolarizer have been shown to improve results in diminishing SCh-induced
postoperative myalgia (Melnick, Chalasani, Uy, Phitayakorn, Mallett, & Rudy,
1987). These potential benefits formed the basis of support for this author's
choices of study pretreatment medications.
As expected, due to the small sample size, analysis of data between
postoperative myalgia and the efficacy of each pretreatment group did not reveal
any of the pretreatments as superior for preventing postoperative myalgia.
Recalling the study design, the three pretreatment groups were as follows:
atracurium 0.05 mg/kg, lidocaine 1 . 5 mg/kg, or the combination group of both
atracurium 0.05 mg/kg and lidocaine 1.5 mg/kg. Principal findings included the
atracurium group having the most pain on postoperative day one, as 60% of the
subjects within this group reported postoperative myalgia. Additionally, this
group reported the most intense pain. The lidocaine and combination groups
were comparable, as each reported a 50% incidence of postoperative myalgia on
day one. Also, the combination group had the least intense pain. These findings
are congruent with the literature (Raman & San, 1997). However, on day two,
although the atracurium group exhibited the most intense pain, it was found to
have a decreased amount of pain, as only 40% of subjects reported
postoperative myalgia. Both the lidocaine and combination group exhibited the
same amount of reported pain (50%) , with the lidocaine group decreasing in
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intensity and the discomfort of subjects in the combination group remaining the
same as postoperative day one. By day three, this study found only 20% of
subjects within the atracurium group to report myalgia. Additionally, this group
reported the least intense pain of all three groups, followed by the combination
group and then the lidocaine group. These findings are surprising, as it is
inconsistent with the literature. Wong and Chung (2000), as well as Melnick,
Chalasani, Uy, Phitayakorn, Mallett, and Rudy (1987), found that combination
therapy was the best pretreatment therapy for postoperative myalgia.
One possible reason for such differing findings in this pilot study may have
been related to the timing of lidocaine administration. One study by Laurence
(1987), found that lidocaine 1.5 mg/kg was ineffective in reducing postoperative
myalgia when it was given two to three minutes prior to SCh. This was the
administration routine in this author's study. Melnick (1987), however, found that
lidocaine 1.5 mg/kg was effective at preventing postoperative myalgia, as long as
it was given 15 to 30 seconds prior to SCh. Therefore, in a larger study, this may
be a factor in producing similar findings within the literature. More importantly,
this variable could be a plausible explanation for decreased postoperative
myalgia.
ASA Physical Status Classification and Cigarette Smoking
To date, there are not any studies indicating that either ASA PSC or cigarette
smoking would have an effect on postoperative myalgia. However, despite
pretreatment, this data analysis indicated that some clinical significance might
exist between ASA PCS, cigarette smoking, and postoperative myalgia. In this
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authofs study, 80% of ASA PCS I I subjects complained of pain, while only
37.5% of ASA PCS I subjects had discomfort. Interestingly enough, 50% of the
ASA PCS I I subjects (two subjects) were also smokers. Although the small
number of subjects prevents any generalizations to other populations (N=2), an
interesting correlation was identified, which might prove to be a focus for future
investigation. Such information could lead one to believe that perhaps ASA
PCS and/or cigarette smoking may contribute to the development of
postoperative myalgia. Thus, further study is needed in this area.
Confounding Variables
After putting this research study into action, several surprising confounding
variables were identified. These factors made data collection more difficult and
time consuming than anticipated. The most significant variable was with issues
within the pharmacy. Because only one pharmacist works within this institution's
surgical suite, and each subjects' dose of medication was customized by their
weight, an average of forty-five minutes advanced notice was required to
compound the needed regimen. Therefore, often times, enrolled subjects were
excluded because of insufficient time to allow the pharmacist to compound the
pretreatment medications. Access to a research pharmacist would have
significantly decreased this time period, and allowed for inclusion of many more
subjects.
Additionally, because this author was responsible for the identifying plausible
subjects, obtaining informed consent, notifying pharmacy, and providing the
anesthetic care for the subject, there was limited ability to access eligible
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subjects early enough for enrollment. In future studies, such variables could
easily be avoided if one researcher were assigned to research duties, while
another performed the anesthetic care.
Limitations
This pilot study attempted to control for outside variables that were identified
in the literature as causative factors for postoperative myalgia. Such factors
included age, dose of SCh, type of operation, positioning of the patient, and
ambulation after surgery (Wong & Chung, 2000). Despite such attention to
detail, this author has noted several additional limitations for this pilot study. The
following will summarize such instances, and recommend that a larger study
incorporate controls in these areas in an effort to strengthen f uture research.
As accepted by the nature of the project, one limitation of a pilot study is the
sample size. This study's population consisted of a small convenience sample of
15 subjects. Therefore, generalizations could not be made to any other
populations. Additionally, gender specific information would be difficult to attain
since this group was comprised of only two male subjects and 13 female
subjects. However, this study was successfully implemented and it did
determine feasibility to gather the needed information in order to complete a
larger study. Since this goal was the overall purpose, the pilot study should be
viewed as wholly successf ul and beneficial.
Another limitation of this study is that it did not include a control group.
Because past research has identified that postoperative myalgia occurs in 50%
of the population receiving SCh without pretreatment, this author felt it unethical
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to include such a group in the study design (Wong & Chung, 2000). However,
past studies have also identified a 20.8% incidence of postoperative myalgia for
subjects who did not receive any pretreatment muscle relaxant before the
administration of SCh (Trepanier, Brousseau, & Lacerte, 1988). Therefore, a
control group could have been useful in identifying whether pretreatment
medications made a difference in postoperative pain; Or " if the observed results
were a phenomena due to some other factor.
Some studies have implicated intubation as a causative factor of
postoperative neck myalgia (Trepanier, Brousseau, & Lacerte, 1988).
Incorporating a_n assessment tool to evaluate the ease or difficulty of intubation,
and then comparing this score to those subjects who complained of
postoperative neck myalgia, could strengthen the overall outcome of a larger
study. This analysis would allow for differentiation between SCh-induced
postoperative myalgia and positioning-induced postoperative neck myalgia.
Strengths
It is ironic that one of the greatest observed strengths of this author's study
was thought to be a weakness at the beginning of the investigation. The
assessment of postoperative myalgia for three days was thought to have many
factors that would inhibit data collection. However; this author observed that all
of the participants actually enjoyed being called by the researcher, and were
more than happy to provide any information that was requested. As a result, this
aspect of the study proved to .be an excellent public relations venture for this
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surgical center. While completely unexpected, it demonstrates a value-added
aspect to clinical research focusing on human subjects.
Additional strengths included assessment of not only the amount of pain
(PMS), but also differentiating postoperative myalgia from surgical pain, as well
as describing the intensity of postoperative muscle soreness (PMES). Past
studies have focused on either PMS or PMES, but not both. Consequently,
former studies have had difficulty in distinguishing myalgia from surgical pain.
This author very quickly realized the importance of using both tools in this
investigation. For example, the PMS was sensitive enough to help the
investigator assure the subject was experiencing true myalgia, and not shoulder
discomfort from surgical gas. Using two valid assessment tools strengthens the
findings, and provides a more complete picture of postoperative myalgia in this
pilot study. Therefore, suggesting that a larger project utilizing the same type of
assessment tools and framework should be able to provide more complete
answers to the mystery of postoperative myalgia.
· Conclusion
Overall, this pilot study accomplished its purpose, thereby determining
feasibility for a larger study. Although not statistically significant, the data
obtained through the implementation of this pilot study identified areas that are
clinically significant. Study results also identified other potential causative factors
for postoperative myalgia, such as ASA PCS, cigarette smoking, surgical
position, prior use of pain medications, and surgical type. Because so much
remains controversial about the phenomena of postoperative myalgia, this
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remains an area where intense research needs to be applied, so as to determine
which interventions constitute the best practices to provide better care in the
future.

94

REFERENCES

95

References
Anderson, K. N., Anderson, L. W., & Glanze, W. D. (Eds). (1998). Mosby's
medical, nursing, & allied health dictionary (5th ed.). St. Louis, MO: Mosby.
Baraka, A. (1977). Self-taming of succinylcholine-induced fasciculations.
Anesthesiology, 46, 292-293.
Brodsky, J. B., & Brock-Utne, J. G. (1979). Does "self-taming" with
succinylcholine prevent postoperative myalgia? Anesthesiology, 50 (3), 265267.
Brodsky, J. 8., Brock-Utne, J. G., & Samuels, S. I. (1979). Pancuronium
pretreatment and post-succinylcholine myalgias. Anesthesiology, 51 (3), 259261.
Brodsky, J. B., & Ehrenwerth, J. (1980). Postoperative muscle pains and
suxamethonium. British Journal of Anaesthesia, 52, 215-218.
Chatterji, S., Thind, S. S., & Daga, S. R. (1983). Lignocaine pretreatment for
suxamethonium: A clinicobiochemical study. Anaesthesia, 38, 867-870.
Chestnut, W. N., Lowry, K. G., Dundee, J. W., Pandit, S. K. & Mirakhur, R. K.
(1985). Failure of two benzodiazepines to prevent suxamethonium-induced
muscle pains. Anaesthesia, 40, 263-269.
Chestnut, W. N., & Dundee, J. W. (1985). Failure of magnesium sulfate to
prevent suxamethonium induced muscle pains. Anaesthesia, 40, 488-490.
Chestnutt, W. N., Lowry, K. G., Dundee, J. W., Pandit, S. K., & Mirakhur, R. K.
(1985). Failure of two benzodiazepines to prevent suxamethonium-induced
muscle pain. Anaesthesia, 40, 263-269.
97

Churchill-Davidson, H . C. (1954). Suxamethonium (succinylcholine) chloride and
muscle pains. British Medical Journal, 1, 74-75.
Churchill-Davidson, H. C. (1984). Neuromuscular blocking drugs. In H. C.
Churchill-Davidson (Ed.), A practice of anaesthesia (pp.676-707). Chicago,
IL: Year Book Medical Publishers Incorporated.
Collier, C. B. ( 1978). Suxamethonium pains and early electrolyte changes.
Anaesthesia, 33, 454-461.
Collier, C. B. (1979). Dantrolene and suxamethonium. Anaesthesia, 34, 152158.
Crawford, J. S. (1971). Suxamethonium muscle pains and pregnancy.· British
Journal of Anaesthesia, 43, 677-680.
Deehan, S., Henderson, D., & Stewart, K. (2000). Intubation conditions and
postoperative myalgia in outpatient dental surgery: A comparison of
succinylcholine and mivacurium. Anaesthesia Intensive Care, 28, 146-150.
Demers-Pelletier, J., Drolet, P., Girard, M., & Donati, F . (1997). Comparison of
rocuronium and d-tubocurarine for prevention of succinylcholine-induced
fasciculations and myalgia. Canadian Journal of Anaesthesia, 44 (11 ), 11441147.
Eisenberg, M., Balsley, S., & Katz, R. L. (1979). Effects of diazepam on
succinylcholine-induced myalgia, potassium increase, creatine phosphokinase
elevation, and relaxation. Anesthesia & Analgesia, 58 (4), 314-317.
Evans, F. T., Gray, P. W. S., Lehmann, H., & Silk, E. (1952). Sensitivity to
succinylcholine in relation to serum-cholinesterase. The Lancet, 1229-1230.
98

Fahmy, N. R. , Malek, N. S., & Lappas, D. G. (1 979). Diazepam prevents some
adverse effects of succinylcholine. Clinical Pharmacology & Therapeutics, 26,
395-398.
Ferrante, F. (1 998) . Acute postoperative pain management. I n D. E.
Longnecker, J . H. Tinker, & G. E. Morgan (Eds.), Principles and practice of
anesthesiology r1 ed. (pp. 2331 -2351 ).
Foldes, F. F . , McNall, P. G . , & Borrego-Hinojosa, J. M. (1 952). Succinylcholine:
A new approach to muscular relaxation in anesthesiology. The New England
Journal of Medicine, 247 ( 1 6), 596-600.
Foster, C. A. (1 960). Suxamethonium and muscle pains. British Medical
Journal, 2, 24-25.
Glauber, D. (1 966). The incidence and severity of muscle pains after
suxamethonium when preceded by gallamine. British Journal of Anaesthesia,

38, 541 -544.
Griffith , H. R., & Johnson, G. E. (1 942) . The use of curare in general
anesthesia. Anesthesiology, 3, 41 8-420.
Gupte, S. R., & Savant, N. S. ( 1 97 1 ). -Post suxamethonium pains and vitamin C.
Anaesthesia, 26, 436-440.
Gysai H. K. , Delisle, S., & Bevan, D. R. (1 982). Succinylcholine fasciculations:
Failure of suppression by small doses of dantrolene. Canadian
Anesthetist's Society Journal, 29, 503.
Haldia, K. N . , Chatterji , S., & Kackar, S. N. (1 973). Intravenous lignocaine for
prevention of muscle pain after succinylcholine. Anesthesia and Analgesia,
99

52 (5), 849-852.
Harris, F. A. (1984). In J . V. Basmajian (Ed.), Therapuetic exercise. (pp. 1 10).
Baltimore, MD: Williams and Wilkins.
Hartman, G. S., Fiamengo, S. A., & Riker, W. F. ( 1986). Succinylcholine:
mechanism of fasciculations and their prevention by d-tubocurarine or
diphenylhydantoin. Anesthesiology, 65, 405-413.
Hatta, V. , Saxena, A., & Kaul, H. L. (1992). Phenytoin reduces suxamethonium
induced myalgia. Anaesthesia, 47, 664-667.
Hochhalter, C. M. ( 1996) . Evaluation of succinylcholine-induced fasciculations
and myalgias with or without atracurium pretreatment. Journal of American
Association of Nurse Anesthetists, 64 (4) , 336-340.

Houghton, I. T . , Aun, C. S. T., Gin, T . , Lau, J . T. F., & Oh, T. E. ( 1993).
Suxamethonium myalgia: An ethnic comparison with and without
pancuronium pretreatment. Anaesthesia, 48, 377-38 1 .
Hunt, R. , & Taveau, R. M . (1906) . On the physiological action of certain choline
derivatives and new methods for detecting choline. The British Medical
Journal, 2, 1788-179 1.

Kahraman, S. , Ercan, S. , Aypar, U., & Erdem, K. (1993) . Effect of preoperative I .
M . administration of diclofenac on suxamethonium-induced myalgia. British
Journal of Anaesthesia, 71, 238-241.

Kitamura, S. , Yoshiya, I , Tashiro, C. , & Negishi, T. (198 1). Sch causes
fasciculation by prejunctional mechanism. Anesthesiology, 55 (3), A22 1 .
Laurence, S . ( 1985). Oral dantrolene prevents rise of myoglobin due to
100

suxamethonium. Anaesthesia, 40, 907-91 0.
Leeson-Payne, C. G., Nicoll, J. M. V. , & Hobbs, G. J. (1 994). Use of ketrolac in
the prevention of suxamethonium myalgia. British Journal of Anaesthesia, 73,
788-790.
Magee, D. A. , & Robinson, R. J. S. (1 987). Effect of stretch exercises on
suxamethonium induced fasciculations and myalgia. British Journal of
Anaesthesia, 59, 596-601 .

Manataki, A. D., Arnaoutoglou , H . M., Tefa, L. K., Glatzounis, G. K. , &
Papadopoulos, G. S. (1 999). Continuous propofol administration for
suxamethonium-induced postoperative myalgia. Anaesthesia, 54, 41 9-422.
Martin, R. , Carrier, J., Claprood Y. , & Tetrault, J . P. (1 998). Rocuronium is the
best non-depolarizing relaxant to prevent succinylcholine fasciculations and
myalgia. Canadian Journal of Anaesthesia, 45 (6) , 521 -525.
Mcloughlin , C., Elliot, P., McCarthy, G. & Mirakhur, R. K. (1 992). Muscle pains
and biochemical changes following suxamethonium administration after six
pretreatment regimens. Anaesthesia, 47, 202-206.
Mcloughlin, C., Nesbitt, G. A. , & Howe, J. P. (1 988). Suxamethonium induced
myalgia and the effect of preoperative administration of oral aspirin.
Anaesthesia, 43, 565-567.

Melzack, R., & Wall, P. (1 965). Pain mechanisms: A new theory. Science, 15,
971 -979.
Mikat-Stevens, M., Sukhani, R., Pappas, A. L., Fluder, E., Kleinman, B., &
Stevens, R. A. (2000). Is succinylcholine after pretreatment with
1 01

d-tubocurarine and lidocaine contraindicated for outpatient anesthesia?

Anesthesia & Analgesia, 91, 312-316.
Melnick, 8. , Chalasani, J. , Uy, N. T. , L. , Phitayakorn, P. , Mallett, S. V. , & Rudy, T.
E. (1987). Decreasing post-succinylcholine myalgia in outpatients. Canadian

Journal of Anaesthesia, 34 (3), 238-241.
Mingus, M. L. Shamsi, A. K. , Recant, J. F., & Eisenkraft, J. B. (1996). Propofol
permits tracheal intubation but does not affect postoperative myalgias.

Journal of Clinical Anesthesia, 8, 220-224.
Mingus, M. L. , Herlich, A. , & Eisenkraft, J. B. (1990). Attenuation of
suxamethonium myalgias. Anaesthesia, 45, 834-837.
Morgan, G. E. , & Mikhail, M.S. (1996). Muscle relaxants. Clinical

anesthesiology,

r1 edition,

(pp. 149-164). New York, NY: Lange Medical

Books/McGraw-Hill.
Newman, P. T. F. , & Loudon, J. M. (1966). Muscle pain following administration
of suxamethonium: The aetiological role of muscular fitness. British Journal of
Anaesthesia, 38, 533-539.
O'Sullivan, E. P. , Williams, N. E. , & Calvey, T. N. (1988). Differential effects of
neuromuscular blocking agents on suxamethonium-induced fasciculations
and myalgia. British Journal of Anaesthesia, 60, 367-371.
Oxorn, D. C. , Whatley, G. S. , Knox, J. W. D. , & Hooper, J. (1992). The
importance of activity and pretreatment in the prevention of suxamethonium
myalgias. British Journal of Anaesthesia, 69, 200-201.
Pace, N. L. (1990). Prevention of succinylcholine myalgias: A meta-analysis.
102

Anesthesia & Analgesia, 70, 477-483.
Pinchak, A. C. , Smith, C. E., Shepard, L. S., & Patterson, L. (1994). Waiting
time after non-depolarizing relaxants alter muscle fasciculation response to
succinylcholine. Canadian Journal of Anaesthesia, 41 (3), 206-212.
Pino, R. M., & Basta, S. J . (1998). Pharmacology of neuromuscular blocking
drugs. In D. E . Longnecker, J. H. Tinker, & G. E . Morgan (Eds.), Principles
and practice of anesthesiology, (pp. 765-790). St. Louis, MO: Mosby.
Raman, S. K., & San, W. M. (1997). Fasciculations, myalgia and biochemicali
changes following succinylcholine with atracurium and lidocaine pretreatment.
Canadian Journal of Anaesthesia, 44 (5), 498-502.
Resnick, B. , & Henze, R. (2000). Normal and altered functions of the
musculoskeletal system. In B. Bullock & R. Henze (Eds.), Focus on
pathophysiology (pp. 793-800). Philadelphia, PA: Lippincott, Williams, &
Wilkins.
Sackett, K. , & Cannon, C. (2000). In B. Bullock & R. Henze (Eds.), Focus on
pathophysiology (pp. 1047-1060). Philadelphia, PA: Lippincott, Williams , &
Wilkins.
Shrivastava, 0. P. , Chatterji, S. , Suman, K., & Daga, S. R. (1983). Calcium
gluconate pretreatment for prevention of succinylcholine-induced myalgia.
Anesthesia and Analgesia, 62, 59-62.
Stacey, M. R. W., Barclay, K. , Asai, T. , & Vaughan, R. S. (1995). Effects of
magnesium sulphate on suxamethonium-induced complications during rapid
sequence induction of anaesthesia. Anaesthesia, 50, 933-936.
103

Sosis, M., �road, T., Larijani, G. E., & Marr, A. T. (1987). Comparison of
atracurium and d-Tubocurarine for prevention of succinylcholine myalgia.
Anesthesia & Analgesia, 66, 657-659.
Stoelting, R. K. (1987). Neuromuscular blocking drugs. In L. Reines, S.J.
Robinson, & H. Ewan (Eds.), Pharmacology and physiology in anesthetic
practice (pp. 169-213). Philadelphia, PA: J. B. Lippincott Company.
Stoelting R. K., & Miller, R. D. (2000). Neuromuscular blocking drugs. Basics of
anesthesia, 4th edition (pp.89-105). San Francisco, CA: Churchill-Livingstone.
Syed, I. H. (1966). Muscle stiffness and vitamin C. British Medical Journal of
Anaesthesia, 2, 304.
Trepanier, C. A., Brousseau, C., & Lacerte, L. (1988). Myalgia in outpatient
surgery: Comparison of atracurium and succinylcholine. Canadian Journal of
Anesthesia, 35, (3), 255-259.
Tsui, B. C. H., Reid, S., Gupta, S., Kearney, R., Mayson, T., & Finucane, B.
(1998). Reports of Investigation: A rapid precurarization technique using
rocuronium. Canadian Journal of Anaesthesia, 45 (5), 397-401 .
Usubiaga, J . E., Wikinski, J. A., Usubiaga, L. E., & Molina, F . (1967}.
Intravenous lidocaine in the prevention of postoperative muscle pain caused
by succinylcholine administration. Anesthesia and Analgesia, 46, 225-230.
Verma, R. S., Chatterji, S., & Mathur, N. (1978). Diazepam and succinylcholine
induced muscle pains. Anesthesia & Analgesia, 57, 295-297.
Wong S. F., & Chung, F. (2000). Succinylcholine-associated postoperative
myalgia. Anesthesia, 55, 144-152.
1 04

APPENDICES

105

Appendix A
ASA Physical Status Classification
http://www.asahq.org/clinical/physicalstatus.htm
ASA Physical Status Classification
Class 1

A normal healthy patient.

Class 2

A patient with mild systemic disease and no functional limitations.

Class 3

A patient with moderate to severe systemic disease that results in
some functional limitations.

Class 4

A patient with severe systemic disease that is a constant threat to life
and functionally incapacitating.

Class 5

A moribund patient who is not expected to survive 24 hours with or
without surgery.

Class 6

A brain-dead patient whose organs are being harvested.

Class E

If the procedure is an emergency, an "E" follows the physical status
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Appendix B
Study Formulary
Study Formulary: Indications, contraindications, and adverse effects are from
Micro Medex®. All dosages are commonly administered and accepted ranges for
use in anesthesia. It is important to note that responses to adverse effects are
not drug specific, and anesthesia providers will respond in a uniform way.
❖ Albuterol (Proventil) 1 -2 puffs prn
► Indications
• bronchospasm
• exercised induced asthma
► Contraindications
• hypersensitivity to albuterol
► Adverse effects
• bronchospasms
• arrhythmias
• tremors/nervousness
• palpitations
• tachycardia
• hypertension
• hypokalemia
• hyperglycemia
❖ Atracurium (Tracrium) 0.05 mg/kg (defasciculating dose)
► Indications
• muscle relaxation
• adjunct to anesthesia
► Contraindications
• hypersensitivity to atracurium
► Adverse effects
• flushing
• hypotension
• bradycardia
• bronchospasm
• tachycardia
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❖ Atropine Sulfate 0.4 - 1 .0 mg
► I ndications
• symptomatic bradycardia
• bradyarrhythmias
► Contraind ications
• narrow angle glaucoma
• myasthenia gravis
• paralytic ileus
► Adverse effects
• tachycardia
• slight mydriasis
• hot, flushed skin
❖ Dobutamine hyd rochloride (Dobutrex) 2.5 - 1 0 mcg/kg/min
► Indications
• increase cardiac contraction
► Contraindications
• hypersensitivity to Dobutamine hydrochloride
• hypersensitivity to sulfonamides .
• IHSS (idiohypertrophic subaortic stenosis
► Adverse effects
• increased heart rate
• hypertension
• premature ventricular contractions
❖ Decadron (Dexamethasone) 4-Smg
► Indications
• ad renal insufficiency
• inflammatory disorders
• nausea/vomiting
• shock
► Contraindications
• hypersensitivity to class
• systemic fungal infection
► Adverse effects
• ad renal insufficiency
• steroid insufficiency
• immunosuppression
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❖ Dolasetron (Anzemet) 1 2.5 mg
► Indications
• antiemetic
► Contraindications
• hypersensitivity to dolasetron products
► Adverse effects
• headache
• dizziness
• drowsiness
• pain
❖ Dopamine hydrochloride (lntropin) 2- 20 mcg/kg/min
► Indications
• correct hypotension
• increase cardiac output
• improve perfusion
► Contraindications
• uncorrected tachyarrythmias
• pheochromocytoma
• ventricular fibrillation
► Adverse effects
• arrhythmias
• hypotension
❖ Ephedrine 5-1 0 mg pm
► Indications
• asthma
• hypotension
► Contraindications
• hypersensitivity to ephedrine/sympathomimetic amines
• thyrotoxicosis
► Adverse effects
• central nervous system stimulation
• hypertension
• palpitations
• tremor

1 10

❖ Epinephrine hyd rochloride (Adrenalin Chloride} 0.01 - 0.03 mcg/kg/min
► Indications
• anaphylaxis
• bronchospasm
• restore cardiac rhythm
► Contraindications
• narrow angle glaucoma
• coronary insufficiency
• organic brain damage
► Adverse effects
• hypertension
• tachycardia
• ventricular fibrillation
❖ Esmolol (Brevibloc} 0.25 mg/kg � 1 .0 mg/kg
► Indications
• supraventricular tachycardia
• hypertension
► Contraindications
• hypersensitivity to esmolol/ beta-blockers
• sinus bradycardia
• 2nd , 3rd, degree AV block
• cardiogenic shock
► Adverse effects
• bronchospasm
• severe hypotension
• cardiac failure
• nausea and vomiting
• phlebitis
❖ Fentanyl (Sublimaze} 0.7- 2 mcg/kg
► Indications
• pain
• analgesic adjunct to anesthesia
• anesthesia
• acute or postoperative pain
► Contraindications
• hypersensitivity to Fentanyl
► Adverse effects
• respiratory depression
• muscle rigidity
• nausea and vomiting
• sedation
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❖ Glycopyrrolate (Robinal) 0.007mg/kg
► Indications
• gastric and salivary secretion reduction
• vagal-mediated bradycardia
• peptic ulcer
• neuromuscular blockade reversal
► Contraindications
• glaucoma
• obstructive uropathy
• myasthenia gravis
• severe ulcerative colitis
• unstable cardiovascular status
► Adverse effects
• dry mouth
• blurred vision
• tachycardia
• urinary retention
❖ Granisetron Hydrochloride (Kytril) 1 0-20mcg/kg
► Indications
• postoperative nausea and vomiting
► Contraindications
• hypersensitivity to grainisetron products
► Adverse effects
• headache
• constipation
• asthenia
• diarrhea
• abdominal discomfort
❖ Hydroxyl ethyl starch (Hextend) 6% 20 mUkg
► Indications
• volume expander
• hypotension
• blood loss
► Contraindications
• hypersensitivity
► Adverse reactions
• hypertension
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❖ Ketrolac (Toradol) 30mg
► Indications
• short-term management of . pain
► Contraindications
• hypersensitivity to nonsteroidal anti-inflammatory drugs
• gastrointestinal ulcers
► Adverse effects
• edema
• hypertension
• puritus
• nausea
• vomiting
• G. I. bleeding
• flushing
❖ Labatolol (Trandate) 0.1 - 0.25 mg/kg
► Indications
• hypertension
• hypertension emergency
► Contraindications
• hypersensitivity to labatolol/ beta-blockers
• congestive heart failure
• hepatic failure
• pheochromocytoma
■
2nd , 3 rd , degree AV block
• severe bradycardia
► Adverse effects
• ventricular arrhythmias
• bronchospasm
• SLE
• hypotension
• nausea and vomiting
• urinary retention
• rash
• muscle spasms
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❖ Lidocaine (Xylocaine) 1 .5. mg/kg

► Indications
• ventricular arrhythmias
• anesthesia
► Contraindications
• hypersensitivity to lidocaine/amide-type anesthetics
► Adverse effects
• seizures
• drowsiness
• tremors
• hypotension

❖ Midazolam (Versed) 0.02-0.1 mg/kg

► Indications
• anesthesia induction
• conscious sedation
► Contraindications
• acute narrow angle glaucoma
• hypersensitivity to benzodiazepines
► Adverse effects
• amnesia
• nausea and vomiting
• respiratory depression

❖ Morphine 0.05 - 0 .2 mg/kg

► Indications
• for management of moderate to severe pain
• preoperative sedation
• anesthesia supplement
► Contraindications
• hypersensitivity to opiates
• paralytic ileus
• acute/severe asthma
• upper airway obstruction
► Adverse effects
• hypotension
• respiratory depression
• nausea
• sedation
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❖ Neostigmine (Prostigmine) 0.04 - 0.07mg/kg
► Indications
• myasthenia gravis
• neuromuscular blockade reversal
• post-op paralytic ileus
• urinary retention
► Contraindications
• hypersensitivity to neostigmine
• intestinal or urinary obstruction
• peritonitis
► Adverse effects
• bradycardia
• psychosis
• agitation
• abdominal distention
• constipation
❖ Nitroglycerin (Deponit) 0.1 - 7 .0 mcg/kg/min
► Indications
• To control hypertension associated with surgery
► Contraindications
• hypersensitivity to nitrites
• head trauma
• severe anemia
► Adverse effects
• hypotension
• tachycardia
• flushing
❖ Nitrous Oxide 1 0 - 70°/4
► Indications
• anesthetic adjunct
► Contraindications
• pneumothorax
• increased intracranial pressure
• increased lntraocular pressure
► Adverse effects
• nausea/vomiting
• abdominal distention
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❖ Ondansetron Hydrochloride (Zofran) 4 mg
► Indications
• nausea and vomiting
► Contraindications
• hypersensitivity to ondansetron
► Adverse effects
• elevated liver function tests
■
headache
• diarrhea
❖ Phenylephrine (Neo-synephrine) 50-1 00 mcg pm
► Indications
• decongestant
• hypotension
► Contraindications
• hypersensitivity to phenylephrine
• narrow angle glaucoma
• hypertension
• coronary artery disease
► Adverse effects
• tachycardia
• hypertension
• myocardial infarction
• subarachnoid hemorrhage
❖ Promethazine (Phenergan) 6.25 - 25mg
► Indications
• nausea and vomiting
• sedation
• allergic reactions
► Contraind ications
• narrow-angle glaucoma
• peptic ulcer disease
• prostatic hypertrophy
• bladder obstruction
• MAOI therapy
• hypersensitivity to phenothiazines
► Adverse effects
• drowsiness
• xerostomia
• dizziness
• extra pyramidal reactions
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❖ Propofol (Diprivan) 2-2.5 mg/kg
► Indications
• anesthesia
• sedation
► Contraindications
• hypersensitivity to eggs
► Adverse effects
• seizures
• hypotension
• apnea
• injection site pain
• cardiac arrest
❖ Sevoflurane (Ultane) 0.5 - 6%
► Indications
• anesthesia
► Contraindications
• hypersensitivity to sevoflurane
• patients with susceptibility to malignant hyperthermia
► Adverse effects
• nausea and vomiting
• excitatory movements
• respiratory depression
• decreased heart rate
❖ Succinylcholine (Anectine) 1 .5mg/kg
► Indications
• muscle relaxation
• intubation
► Contraindications
• malignant hyperthermia
• acute phase of major trauma/major burns
• hypersensitivity to succinylcholine
• skeletal muscle myopathies
• upper motor neuron injury
► Adverse effects
• myoglobinemia
• prolonged muscle relaxation
• bradycardia
• hyperkalemia
• respiratory depression/apnea
• hypersensitivity reactions
• cardiac arrest
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❖ Vecuronium (Norcuron) 0.05- 0.1 mg/kg
► Indications
• muscle relaxation
► Contraindications
• hypersensitivity to pancuronium or vecuronium products
► Adverse effects
• bronchospasm
• bradycardia
• hypotension/hypertension
• tachycardia
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Appendix C
Informed Consent
A Comparison of the Differential Effects of Atracurium and/or Lidocaine on
Succinylcholine-induced Fasciculation and severity of Postoperative
Myalgia
Investigators
Jack Chavez M.D., Fred Schrimpe, BSN, SRNA, Tonya Campbell, BSN,
SRNA
Informed Consent
The study in which you are asked to participate has the goal of reducing muscle
twitching and muscular soreness after surgery, which can occur with
succinylcholine administration. This is a topic that is frequently studied. Many
scientists feel that the muscle soreness some people experience after surgery is
related to the muscle twitching occurring with succinylcholine administration. You
are being asked to participate because you are in a group of patients who
frequently have muscle soreness after surgery, namely, patients receiving
succinylcholine for general tracheal anesthesia.
Succinylcholine is a muscle relaxant that allows your anesthesia provider to
place a breathing tube in your windpipe to protect your airway after you are
asleep. This tube allows you to breath the anesthetic gases that will keep you
asleep. This is done routinely for general anesthesia and will be required
regardless of your participation in this study. You should be unaware of this tube
placement and should not remember it. All subjects will be selected from the
daily surgical schedule at the University of Tennessee Medical Center.
This study will examine two anesthetic medications that are routinely used to
prevent muscular twitching and soreness. Neither drug has been proven superior
in preventing muscle twitching or muscular soreness. We are asking permission
to do two things during this study. First, to record any muscular twitching we may
observe, and second, to ask you some simple questions after surgery about
whether you are experiencing any muscular soreness. You will be contacted by
phone 24, 48, and 72 hours after your surgery by one of the investigators. ·1 f your
surgeon admits you to the hospital, you will be visited in your room by one of the
investigators.
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· A Comparison of the Differential Effects of Atracurium and/or Lidocaine on
Succinylcholine-ind�ced Fasciculation and severity of Postoperative
Myalgia
Investigators
Jack Chavez M.D., Fred Schrimpe, BSN, SRNA, Tonya Campbell, BSN,
SRNA

· The medications used will consist of a muscle relaxant (atracurium), or local
anesthetic/numbing (lidocaine) medication. Some patients may receive both
medications. These medications will be administered in a double blind method.
This means that neither you nor the anesthesia provider will know which drug
was given until the conclusion of the study. The doses of the medicines,
however, will be carefully and safely prepared for you under the supervision of a
licensed pharmacist. You will receive standard and acceptable doses of all
medications, just as you would if you chose not participate in this study. They will
look the same, and no one except the pharmacist will know what you received
until all the patients have been studied.
You will be assigned a unique number that will be used to identify you and the
information we gather. If something were to happen that required the knowledge
of what drug you received we would use that number to obtain the necessary
information. There may be around 100 patients involved in this study, and it will
probably take several months to gather all the information we need.
Risks Associated with Participation
Since the medications you will receive today are routinely used for anesthetics,
there is essentially no increased risk to you associated with your participation in
this study. However all medications have side effects and could cause adverse
reactions. Although rare, some possible side effects that could occur include
nausea, vomiting, sedation, prolonged muscle weakness, high potassium,
increased body temperature, and seizures.
If you experience the common side effects of pain, nausea, or vomiting after your
surgery, standard medications for these conditions will be administered, just as
they would be for anyone else. You are not expected to experience any
increased discomfort as a result of your participation in this study.
All records are kept confidential. As stated earlier you will be assigned a number
which will be used as your identifier, rather than using your name. These records
will be kept in the Anesthesia Office under lock and key for a period of five years
from the conclusion of the study. After five years, they will be destroyed.
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The hope is to gain information from this study that may help patients in the
future with their post-surgery recovery. The potential benefits to the subjects may
include a more comfortable recovery time and possibly an earlier return to their
pre-surgery level of function. All future patients who undergo surgery and receive
succinylcholine could potentially benefit from this study. If this study
demonstrates that one or the combination of pretreatment medications has
superior ability to diminish or prevent muscle twitching and muscular soreness,
then future patients may experience less discomfort after surgery.
Alternatives to participation
There is no superior drug or treatment to prevent succinylcholine induced muscle
twitches or muscular soreness.
Confidentiality
Although study results may be published, your confidentiality will be maintained.
Your name or information identifying you will not be released without written
permission unless required by law. Under federal privacy regulations, you have
the right to determine who has access to your personal health information (called
"protected health information" or PHI). PHI collected in this study may include
your medical history, the results of physical exams, lab tests, x-ray exams, and
other diagnostic / treatment procedures, as well as basic demographic
information. By signing this consent form, you are authorizing the researchers at
the University of Tennessee Medical Center to have access to your PHI collected
in this study and to receive your PHI from (Jack Chavez M.D.), and may the
University of Tennessee Medical Center where you have received health care. In
addition, your PHI may be shared with other persons involved in the conduct or
oversight of this research, including the (FDA) Food and Drug Administration, the
University of Tennessee Medical Center, and the University of Tennessee
Graduate School of Medicine Institutional Review Board. Your PHI will not be
used or disclosed to any other person or entity, except as required by law, or for
authorized oversight of this research study by other regulatory agencies, or for
other research for which the use and disclosure of your PHI has been approved
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by the IRB. Your PHI will be used indefinitely. You may cancel this authorization
in writing at any time by contacting the Principal Investigator listed on the first
page of the consent form. If you cancel the authorization, continued use of your
PHI is permitted if it was obtained before the cancellation and its use is
necessary in completing the research. However, PHI collected after your
cancellation may not be used in the study. If you refuse to provide this
authorization, you will not be able to participate in the research study.
If you cancel the authorization, then you will be withdrawn from the study.
Finally, the federal regulations allow you to obtain access to your PHI collected or
used in this study. However, in order to complete the research, your access to
this PHI may be temporarily suspended while the research is in progress. When
the study is completed, your right of access to this information will be reinstated.
You understand that you are not waiving any legal rights or releasing the hospital
or its agents from liability for negligence. You understand that in the event of
physical injury resulting from research procedures, the University of Tennessee
does not have funds budgeted for compensation either from lost wages or for
medical treatment. Therefore, the University does not provide reimbursements
for such injuries.
By signing this form, you indicate that: You have read the description of the
above study and have freely volunteered to participate in it. You have had
possible side effects and adverse reactions explained to you and have had
alternative therapies explained. You have had an opportunity to ask questions of
the investigator and have received acceptable answers. You understand you
may withdraw from this study at any time and will still receive standard treatment
for your condition.
Payment for Participation
There is no payment in any form to study participants.
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Costs of Participation

There are no additional costs to you for participating in this study.
Contact/Questions
If you have any questions about the nature of this study, or feel that you have
had an adverse reaction, please feel free to contact Jack Chavez, MD at (865544-9220), Tonya Campbell (865-544-9220), or Fred Schrimpe (865-544-9220).
If you have any questions about your rights as a research subject, please call the
Institutional Review Board at (865-544-9781). Thank you for your consideration.
Consent of Subject
I have read or have had read to me the description of the research study as
outlined above. The investigator or his/her representative has explained the
study to me and has answered all of the questions I have at this time. I have
been told of the potential risks, discomforts, side effects and adverse reactions
as well as the possible benefits (if any) of the study.
I freely volunteer to participate in this study. I understand that I do not have to
take part in this study and that my refusal to participate will involve no penalty or
loss of rights too which I am entitled. I further understand that I am free to later
withdraw my consent and discontinue participation in this study at any time. I
understand that refusing to participate or later withdrawing from the study wi'II not
adversely affect my subsequent medical care.
Signature--------------Date---Date___
Investigator Signature
Witness
Date___
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Appendix D
lnvestigational Review Board Approval Letters
THE UNIVERSITY OF TENNESSEE
GRADUATE SCHOOL OF MEDICINE

Office of lmtitutioaal Review Board
FWA 2301
1924 Alcoa Highway ·
Knoxville, TN 37920-6999
(865) 544-9781
FAX (865) 544-9275

March 20, 2003
Jack Chavez, MD
Department of Anesthesiology
· The University of Tennessee Medical Center
1 924 Alcoa Highway
Knoxville, TN 37920
RE:

IRB #2233 •A Comparison of the Differential Effects of Atracurium and/or
Lidocaine on Succinylcholine-induced Fasciculation and the Severity of
Postoperative Myalgia·

Dear Dr. Chavez,
On March 1 8, 2003, the University of Tennessee Graduate School of Medicine in
Knoxville Institutional Review Board reviewed your above referenced application. The
Board voted full approval with no abstentions on this prot�I including i�formed
consent form. Your research application will be reviewed in one year.
The Institutional Review Board ·is in compliance with the requirements in Part 50,
56, Subch�pter D. Part 31 2 of the 21 Code of Federal·Regulations published January 27,
1 981 .
Any alterations in ·the protocol must be promptly reported to the Institutional
Review Board. In addition, annual reapproval (February 2004} is required by the IRB,
and it is your responsibility as the Principal Investigator to initiate the request'for approval
regardless of the time the study has been approved by the sponsoring agency.
You have individual responsibility for reporting to the Board in the event of adverse

::::
<r-,U.i..

� ��

Joseph E. Fuhr, PhD
Chairman
Institutional Review Board
JEF: rt
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THE UNIVERSITY OF TENNESSEE

Institutional Review Boan:
Office of Rescan±
404 Andy Holt Towei
Knoxville, Tennessee 3 7996.014(
865-974-346t
Fax: 865-974-280�

May 16, 2003
IR.B #: 6413 B

Title: A Comparison of the Differential Effects of Atracurium and/or Lidocaine on
Succinylcholine-induced Fasciculation and Severity of Postoperative Myalgia
Tonya Campbell
Anesthesia
UTMCK.
1924 Alcoa Hwy.

Jack �vez, Co-PI
Anesthesia

UTMCK

1924 _Alcoa Hwy.

Fredrick Schrimpe, Co-PI
Anesthesia

UTMCK

1974 Alcoa Hwy.
.

.

John Preston, Advisor
Nursing
1200 Volunteer Blvd.
Campus
At the meeting of the Institutional Review Board (IRB) held May 15, 2003� the above protocol
was reviewed and approved.
This �val for a period ending one year from the �-of this letter. Please make timely
sub�on of renewal or prompt notificati� of project termination (see item #3 below).
Responsibilities of the investigator during the conduct of this project include the following:
1.

Prior approval from the :Commi� before insti� any changes in the project

2.

To retain signed consent fonns from subjects for at least three years following
completion of the project

3.

To submit a Form D to report changes in the project or to report termination at 12month or less intervals.

The Committee wishes you every success in your research endeavor. · This office will send you a
renewal notice (Form R) on the anniversary of your approval date.

Sincerely,
�A .· -M � �
-�
�

��n
Compliances
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Appendix E
Standard ASA Monitors
AN ESTH ESIA STANDARDS FOR BASIC INTRAOPERATIVE MONITORING
Note: Within these standards, "Anesthesia" is defined as all types of anesthesia
care unless otherwise specified by the text.
STAN DARDS FOR BASIC AN ESTH ETIC MONITORING
(Approved by House of Delegates on October 21 , 1 986 and last amended on
October 2 1 , 1 9981)
http://www. asahq. org/publicationsAndServices/standards/02. html
These standards apply to all anesthesia care although, in emergency
circumstances, appropriate life support measures take precedence. These
standards may be exceeded at any time based on the judgment of the
responsible anesthesiologist. They are intended to encourage quality patient
care, but observing them cannot guarantee any specific patient outcome. They
are subject to revision from time to time, as warranted by the evolution of
technology and practice. They apply to all general anesthetics, regional
anesthetics and monitored anesthesia care. This set of standards addresses only
the issue of basic anesthetic monitoring, which is one component of anesthesia
care. In certain rare or unusual circumstances, 1 ) some of these methods of
monitoring may be clinically impractical, and 2) appropriate use of the described
monitoring methods may fail to detect untoward clinical developments. Brief
interruptions of continualtl monitoring may be unavoidable. Under extenuating
circumstances, the responsible anesthesiologist may waive the requirements
marked with an asterisk (*); it is recommended that when this is done, it should
be so stated (including the reasons) in a note in the patient's medical record.
These standards are not intended for application to the care of the obstetrical
patient in labor or in the conduct of pain management.
STAN DARD I
Qualified anesthesia personnel shall be present in the room throughout the
conduct of all general anesthetics, regional anesthetics and monitored
anesthesia care.
OBJECTIVE
Because of the rapid changes in patient status during anesthesia, qualified
anesthesia personnel shall be continuously present to monitor the patient and
provide anesthesia care. In the event there is a direct known hazard, e.g.,
radiation, to the anesthesia personnel, which might require intermittent remote
observation of the patient, some provision for monitoring the patient must be
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made. In the event that an emergency requires the temporary absence of the
person primarily responsible for the anesthetic, the best judgment of the
anesthesiologist will be exercised in comparing the emergency with the
anesthetized patient's condition and in the selection of the person left responsible
for the anesthetic during the temporary absence.
STANDARD II
During all anesthetics, the patient's oxygenation, ventilation, circulation and
temperature shall be continually evaluated.
OXYGENATION
OBJECTIVE
To ensure adequate oxygen concentration in the inspired gas and the blood
during all anesthetics.
METHODS
Inspired gas: During every administration of general anesthesia using an
anesthesia machine, the concentration of oxygen in the patient breathing system
shall be measured by an oxygen analyzer with a low oxygen concentration limit
alarm in use. *
Blood oxygenation: During all anesthetics, a quantitative method of assessing
oxygenation such as pulse oximetry shall be employed. * Adequate illumination
and exposure of the patient are necessary to assess color. *
VENTILATION
OBJECTIVE
To ensure adequate ventilation of the patient during all anesthetics.
METHODS
Every patient receiving general anesthesia shall have the adequacy of ventilation
continually evaluated. Qualitative clinical signs such as chest excursion,
observation of the reservoir breathing bag and auscultation of breath sounds are
useful. Continual monitoring for the presence of expired carbon dioxide shall be
performed unless invalidated by the nature of the patient, procedure or
equipment. Quantitative monitoring of the volume of expired gas is strongly
encouraged. *
When an endotracheal tube or laryngeal mask is inserted, its correct positioning
must be verified by clinical assessment and by identification of carbon dioxide in
the expired gas. Continual end-tidal carbon dioxide analysis, in use from the time
of endotracheal tube/laryngeal mask placement, until extubation/removal or
initiating transfer to a postoperative care location, shall be performed using a
quantitative method such as capnography, capnometry or mass spectroscopy. *
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When ventilation is controlled by a mechanical ventilator, there shall be in
continuous use a device that is capable of detecting disconnection of
components of the breathing system. The device must g ive an audible sig nal
when its alarm threshold is exceeded .
During regional anesthesia and monitored anesthesia care, the adeq uacy of
ventilation shall be evaluated, at least, by continual observation of qualitative
clinical signs.

CIRCULATION
OBJECTIVE

To ensure the adeq uacy of the patient's circulatory function during all
anesthetics.

METHODS

Every patient receiving anesthesia shall have the ·electrocardiogram conti nuously
d isplayed from the beginning of anesthesia until preparing to leave the
anesthetizing location. *
Every patient receiving anesthesia shall have arterial blood pressure and heart
rate determined and evaluated at least every five minutes. *
Every patient receiving general anesthesia shall have, in addition to the above,
circulatory function continually evaluated by at least one of the following:
palpation of a pulse, auscultation of heart sounds, monitoring of a tracing of intra
arterial pressure, ultrasound peripheral pulse monitoring, or pulse
plethysmography or oximetry.

BODY TEMPERATURE
OBJECTIVE

To aid in the maintenance of appropriate body temperature during all
anesthetics .

METHODS

Every patient receiving anesthesia shall have temperature monitored when
clinically sig nificant changes in body temperature are intended, anticipated or
suspected .
#Note that "continual" is defined as "repeated regularly and frequently in steady
rapid succession" whereas "continuous" means "prolonged without any
interruption at any time."
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Appendix F
Acceptable Hemodynamic Monitoring Parameters
+/- 20% of baseline: Heart rate
+/- 20% of baseline: Blood Pressure
95% or above: Oxygen Saturation
35.6 C (96.0 F) - 37.8 C (1 00.0 F): Temperature
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Appendix G
Extubation Criteria

Train of four is 4/4 without fade, and a positive sustained tetanus
Spontaneous respirations of >8, with a tidal volume of >250
Negative lnspiratory pressure (N IP) of -1 0
Eye opening to voice, or purposeful movement
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Appendix H
Postoperative Myalgia Evaluation Scale (PM'ES)
0 = Absence of pain other than characteristic surgical gas pain
1 = Mild muscle stiffness or pains, when specifically asked about, in the nape of
the neck, or in shoulders and lower chest on deep breathing
2 = Moderate muscle stiffness and pains spontaneously complained of by the
patient
3 = Severe, incapacitating, generalized muscle stiffness or pain
Subject #

1
2

0

1

'

2

3

3

4
5
6
7

8
9

10
11
12
13
14
15
16
17
18
19

20
21
22
23
24
Did the recovery room nurse report the patient shivering in the recovery room?
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Appendix I
Postoperative Myalgia Survey (PMS)
Date of the telephone call___ Postoperative Day: 1_
· 2_ 3_
Date of surgery: __ Type of surgery: __
Subject's study number:
1. Do you have any soreness or stiffness in your body besides headache or
surgical gas pains? Yes_ No_
2. Have you been up and about (ambulatory)? Yes_ No_
3. Is there pain and stiffness in the muscles? Yes_ No _
4. In which sites do you have muscle pain/stiffness?
Jaw_ Throat_ Neck_ Shoulder_ Arms_ Chest_ Abdomen
Back_ Buttocks_ Thighs_ Calves_ General ized_
5. When did you first notice the pain? �
6. Rate the muscle stiffness/pain on a score 0-10 (0 being no pain, and 10 the
worst pain ever) only on the sites reported to be painful by the patient.
Jaw_ Throat_ Neck_ Shoulders_ Arms_ Chest_ Abdomen_
Back_ Buttocks_ Thighs_Calves_ Generalized_
7. What makes the muscle stiffness/pain worse? Movement_ Rest_
8. Describe the muscle pain/stiffness in your own words.
9. Do you think the muscle pain is restricting your normal activity? Yes_ No _
10. Is the muscle pain preventing you from getting out of bed? Yes_ No_
11. How would you rate this limitation of activity on a scale of 0-10? (0 being no
limitation in activity, 10 being muscle pain limiting the patient to bed all the
time except for essential activity)
12. Do you think the muscle pain is severe enough for you to take extra pain
medication? Yes_ No
13. Are you taking your prescribed pain medication to help your surgical pain or
muscle pain? Yes_ No_
14. How many pain pills have you taken the last 24 hours?_
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Appendix J
Demographic Data Sheet and Master Subject List
Name

1
2
3
4
5
6
7
8
9

�

(.tJ
(.tJ

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Phone
#

Subject
#

ASA

w..

in
kg

Ht. in
inches

Gender

Smoking
hx/# of
yrs

Pre-op
NSAID
NARC

Pre-op
NSAI D
NARC

dose

duration

Postop
NSAI D
NARC
dose

Post-op
NSAI D
NARC
duration
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